document type sequence filename description text html head title title head body bgcolor white style margin margin bottom font size font family time roman align right exhibit style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width style font family time roman font size valign align center confidential material omitted filed separately with valign bottom valign style font family time roman font size valign align center security exchange commission double asterisk denote omission valign bottom valign bottom align right execution nbsp version table style margin margin bottom font size font family time roman align center amended restated style margin margin bottom font size font family time roman align center collaboration license agreement style margin margin bottom font size font family time roman align center between style margin margin bottom font size font family time roman align center eisai style margin margin bottom font size font family time roman align center style margin margin bottom font size font family time roman align center epizyme style margin margin bottom font size font family time roman align right confidential style page break before always size style color width align center style margin margin bottom font size font family time roman align center table content style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width valign bottom width width valign bottom width style font family time roman font size valign bottom nbsp valign bottom nbsp nbsp valign bottom nbsp valign bottom nbsp nbsp valign bottom nbsp valign bottom nbsp nbsp valign bottom colspan align center style border bottom solid page valign bottom nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman article nbsp valign bottom nbsp nbsp valign bottom colspan definition valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman article nbsp valign bottom nbsp nbsp valign bottom colspan collaboration overview development activity valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom collaboration overview valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom development activity valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom report result valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom subcontracting valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom regulatory matter compliance valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom transition matter valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman article nbsp valign bottom nbsp nbsp valign bottom colspan commercialization activity diligence manufacturing supply valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom commercialization valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom diligence valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom manufacturing supply valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman article nbsp valign bottom nbsp nbsp valign bottom colspan governance valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom joint steering committee valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom alliance manager valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom senior management meeting valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman article nbsp valign bottom nbsp nbsp valign bottom colspan license grant valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom license grant eisai valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom license grant epizyme valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom right retained party valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom section bankruptcy code valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom access know valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom right negotiation valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman article nbsp valign bottom nbsp nbsp valign bottom colspan financial term valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom reimbursement previous development cost valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom development cost valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom development milestone valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom licensed product royalty valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom blended royalty valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom report royalty payment valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom method payment valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom accounting valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom withholding valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom late payment valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom limitation payment valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom priority review voucher valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp table style page break before always size style color width align center style margin margin bottom font size font family time roman align center table content table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width valign bottom width width valign bottom width style font family time roman font size valign bottom nbsp valign bottom nbsp nbsp valign bottom nbsp valign bottom nbsp nbsp valign bottom nbsp valign bottom nbsp nbsp valign bottom colspan align center style border bottom solid page valign bottom nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman article nbsp valign bottom nbsp nbsp valign bottom colspan exclusivity change control valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom target exclusivity valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom exception valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman article nbsp valign bottom nbsp nbsp valign bottom colspan intellectual property right valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom ownership valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom prosecution maintenance patent valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom patent cost valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom defense claim brought third party valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom enforcement epizyme patent collaboration patent joint patent valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom invalidity unenforceability defense action valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom third party license valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom ownership prosecution product trademark valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman article nbsp valign bottom nbsp nbsp valign bottom colspan confidentiality valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom confidentiality exception valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom product information valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom authorized disclosure valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom press release disclosure agreement valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom termination prior confidentiality agreement valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom remedy valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom publication valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom clinical trial register valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom name valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom return confidential information valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman article nbsp valign bottom nbsp nbsp valign bottom colspan representation warranty valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom representation warranty both party valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom representation warranty epizyme valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom representation warranty eisai valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom mutual covenant valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom disclaimer valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman article nbsp valign bottom nbsp nbsp valign bottom colspan indemnification insurance valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom indemnification eisai valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom indemnification epizyme valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom procedure valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom insurance valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom limitation liability valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman article nbsp valign bottom nbsp nbsp valign bottom colspan term termination valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom term expiration valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom unilateral termination valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom termination cause valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom termination eisai patent challenge valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center table content table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width valign bottom width width valign bottom width style font family time roman font size valign bottom nbsp valign bottom nbsp nbsp valign bottom nbsp valign bottom nbsp nbsp valign bottom nbsp valign bottom nbsp nbsp valign bottom colspan align center style border bottom solid page valign bottom nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom effect termination valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom accrued right surviving provision valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman article nbsp valign bottom nbsp nbsp valign bottom colspan miscellaneous valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom dispute resolution valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom arbitration request valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom governing valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom assignment valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom performance warranty valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom force majeure valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom notice valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom export clause valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom waiver valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom severability valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom entire agreement valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom independent contractor valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom solicitation employee valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom heading construction interpretation valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom book record valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom further action valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom party interest valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom performance affiliate valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom counterpart valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign valign bottom nbsp nbsp valign bottom valign bottom nbsp nbsp valign bottom amendment restatement novation valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp table style margin margin bottom font size font family time roman list exhibit style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width valign bottom width width style font family time roman font size valign exhibit valign bottom nbsp nbsp valign nowrap align center valign bottom nbsp nbsp valign epizyme patent restatement date style font family time roman font size valign exhibit valign bottom nbsp nbsp valign nowrap align center valign bottom nbsp nbsp valign transition matter style font family time roman font size valign exhibit valign bottom nbsp nbsp valign nowrap align center valign bottom nbsp nbsp valign press release style font family time roman font size valign exhibit valign bottom nbsp nbsp valign nowrap align center valign bottom nbsp nbsp valign asia table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center amended restated collaboration license agreement style margin margin bottom text indent font size font family time roman this amended restated collaboration license agreement this agreement entered into made effective style font size vertical align march restatement date between epizyme delaware corporation having principal place business technology square floor cambridge massachusetts epizyme eisai japan corporation having principal place business koishikawa bunkyo tokyo japan eisai epizyme eisai each referred herein name party collectively party style margin margin bottom font size font family time roman align center recital style margin margin bottom text indent font size font family time roman whereas epizyme posse proprietary technology intellectual property identify develop novel small molecule histone methyltransferase inhibitor style margin margin bottom text indent font size font family time roman whereas eisai posse expertise development commercialization each defined below human pharmaceutical style margin margin bottom text indent font size font family time roman whereas eisai epizyme previously entered into collaboration license agreement effective april nbsp such agreement previously amended prior agreement such date prior agreement effective date under which they collaborated with respect development commercialization compound defined below style margin margin bottom text indent font size font family time roman whereas eisai epizyme desire amend restate prior agreement reflect their agreement engage further collaborative effort pursuant which epizyme will carry global development activity directed defined below commercialize resulting licensed product defined below epizyme territory defined below eisai will carry japan specific development activity defined below directed such licensed product commercialize such licensed product eisai territory defined below style margin margin bottom text indent font size font family time roman whereas concurrently with execution this agreement eisai epizyme separately amending restating their letter agreement dated december nbsp regarding their companion diagnostics agreement dated december nbsp existing agreement with roche molecular system amended such amended restated letter agreement amended letter agreement style margin margin bottom text indent font size font family time roman therefore consideration premise mutual covenant herein contained other good valuable consideration receipt sufficiency which hereby acknowledged party hereby agree follows style page break before always size style color width align center style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center definition style margin margin bottom text indent font size font family time roman used this agreement following term will have meaning forth this article unless context dictate otherwise style margin margin bottom text indent font size font family time roman affiliate mean with respect person other person which directly indirectly through nbsp more intermediary control controlled under common control with such person regardless whether such affiliate becomes affiliate after prior agreement effective date person shall deemed control another person nbsp owns directly indirectly beneficially legally more than fifty percent nbsp outstanding voting security capital stock such other person other comparable ownership interest with respect person other than corporation nbsp power whether pursuant contract ownership security otherwise direct management policy such other person style margin margin bottom text indent font size font family time roman applicable commercialization party mean eisai with respect eisai territory epizyme with respect epizyme territory style margin margin bottom text indent font size font family time roman asia mean country identified exhibit style margin margin bottom text indent font size font family time roman bayh dole mean patent trademark amendment amended codified amended well regulation promulgated pursuant thereto including style margin margin bottom text indent font size font family time roman business mean which banking institution boston massachusetts open business excluding saturday sunday style margin margin bottom text indent font size font family time roman calendar quarter mean period three nbsp consecutive month ending last march june september december respectively style margin margin bottom text indent font size font family time roman calendar year mean period twelve nbsp consecutive month beginning january nbsp ending december nbsp style margin margin bottom text indent font size font family time roman cgmp mean governing manufacturing practice intermediate bulk product finished product including regulation forth current good manufacturing practice part rule governing medicinal product european community volume good manufacturing practice medicinal product each amended from time time style margin margin bottom text indent font size font family time roman change control event mean nbsp party nbsp merges consolidates with third party nbsp effect other transaction series related transaction involving transfer capital stock such party third party other than transaction which such party underwriter such party sell security such party nbsp public offering nbsp directly bona fide venture capital investor bona fide institutional investor that routinely make such investment potential financial return such investment with view acquisition case each foregoing clause nbsp nbsp such that stockholder such party immediately prior thereto aggregate longer beneficially more than fifty percent nbsp outstanding voting security surviving entity ultimate parent surviving entity following closing such merger consolidation other transaction series related transaction nbsp such party sell substantially business asset which this agreement relates third party nbsp person group such term defined under section nbsp united state security exchange obtains control defined section nbsp such party style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman clinical trial mean phase clinical trial phase clinical trial phase clinical trial study incorporating more than these phase style margin margin bottom text indent font size font family time roman collaboration mean collaboration know collaboration patent style margin margin bottom text indent font size font family time roman collaboration know mean eisai collaboration know epizyme collaboration know style margin margin bottom text indent font size font family time roman collaboration patent mean eisai collaboration patent epizyme collaboration patent style margin margin bottom text indent font size font family time roman commercialization commercialize mean activity undertaken with respect product relating marketing promotion including advertising detailing medical affair activity medical science liaison activity sponsored product continuing medical education activity post regulatory approval clinical study that required obtain maintain such regulatory approval obtaining pricing reimbursement approval each case with respect such product importing offering sale distribution sale such product identifying screening diagnosing patient potential user such product interacting with regulatory authority regarding foregoing manufacturing commercial supply foregoing activity style margin margin bottom text indent font size font family time roman commercially reasonable effort mean style margin margin bottom text indent font size font family time roman with respect epizyme subject last paragraph this section nbsp such effort that consistent with effort resource normally used epizyme exercise reasonable business discretion relating development commercialization potential pharmaceutical product style margin margin bottom text indent font size font family time roman that similar stage development product life relevant compound licensed compound licensed product style margin margin bottom text indent font size font family time roman that commercial market potential similar relevant compound licensed compound licensed product taking into account issue intellectual property scope subject matter coverage safety efficacy product profile competitiveness marketplace proprietary position profitability including pricing reimbursement status achieved likely achieved royalty other payment required under this agreement style margin margin bottom text indent font size font family time roman with respect eisai such effort that consistent with effort resource normally used eisai exercise reasonable business discretion relating development commercialization potential pharmaceutical product style margin margin bottom text indent font size font family time roman that similar stage development product life relevant compound licensed compound licensed product style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman that commercial market potential similar relevant compound licensed compound licensed product taking into account issue intellectual property scope subject matter coverage safety efficacy product profile competitiveness marketplace proprietary position profitability including pricing reimbursement status achieved likely achieved royalty required under this agreement style margin margin bottom text indent font size font family time roman commercially reasonable effort shall determined country country basis except that party consider impact effort resource expended with respect country other country either party grant sublicense assigns right obligation under this agreement affiliate third party permitted under this agreement then with respect such sublicensee assignee designee commercially reasonable effort shall mean effort resource defined above this section nbsp normally used party granting sublicense assigning right obligation qualified item clause inclusive epizyme sublicensing assigning designating party qualified item clause inclusive eisai sublicensing assigning designating party provided that change control event occurs with respect epizyme person that acquires combine with come control epizyme acquires epizyme asset result such change control event such person then existing affiliate already competing program then from after such change control event commercially reasonable effort with respect epizyme shall than level effort resource normally used company global research based biotechnology pharmaceutical industry qualified item clause inclusive style margin margin bottom text indent font size font family time roman comparable third party product mean with respect therapeutic product country epizyme territory pharmaceutical product sold third party such country authorized behalf epizyme affiliate sublicensees with respect therapeutic product eisai territory pharmaceutical product sold third party eisai territory authorized behalf eisai affiliate sublicensees each case that style margin margin bottom text indent font size font family time roman contains active pharmaceutical ingredient same compound licensed compound contained applicable therapeutic product style margin margin bottom text indent font size font family time roman approved applicable regulatory authority such country more same indication applicable therapeutic product style margin margin bottom text indent font size font family time roman comparable third party product competition mean with respect therapeutic product country territory given calendar quarter that during such calendar quarter style margin margin bottom text indent font size font family time roman more comparable third party product commercially available such country style margin margin bottom text indent font size font family time roman such comparable third party product have market share percent more aggregate market such country such therapeutic product style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman comparable third party product collectively based sale unit such therapeutic product such comparable third party product reported international such data available such other reliable data source reasonably determined epizyme eisai used herein unit product mean equivalent amount product used equivalent treatment cycle such product style margin margin bottom text indent font size font family time roman compound mean small molecule inhibitor style margin margin bottom text indent font size font family time roman control control controlled mean with respect intellectual property right know possession right whether through ownership license other than operation this agreement control defined section nbsp over affiliate with such right grant license sublicenses under such intellectual property right know provided herein without violating term agreement other arrangement with third party notwithstanding foregoing intellectual property right know party that licensed otherwise acquired from third party after prior agreement effective date would otherwise considered under control party shall deemed under control such party application such definition context license grant sublicenses under this agreement would require granting party make additional payment royalty third party connection with such license sublicense grant unless other party agrees additional payment royalty third party subject section nbsp style margin margin bottom text indent font size font family time roman cost good mean party affiliate fully allocated cost manufacturing acquiring from third party licensed compound licensed product development commercialization without markup determined accordance with gaap consistently applied purpose this definition fully allocated cost mean direct identifiable internal external cost charge consisting following style margin margin bottom text indent font size font family time roman with respect manufacturing activity conducted such party affiliate fully allocated cost manufacturing licensed compound licensed product shall consist following cost charge nbsp cost active pharmaceutical ingredient other material packaging component plus inbound outbound freight transportation duty quality assurance testing documentation release drug product other direct material cost nbsp labor cost directly involved with manufacturing acquiring licensed compound licensed product including quality assurance testing documentation release drug product nbsp manufacturing plant overhead charge reasonably allocable licensed compound licensed product including indirect labor indirect expense necessary support manufacturing licensed compound licensed product depreciation purchase price variance other manufacturing variance utility manufacturing management administration cost general supply transportation warehouse equipment maintenance repair installation cost cost other plant service waste treatment waste incineration ongoing stability program cost technical service process design process improvement security each case extent reasonably allocable licensed compound licensed product nbsp direct write offs inventory adjustment loss expired spoiled damaged otherwise unsaleable licensed compound licensed product excluding cost negligence willful misconduct such party affiliate excluding nbsp cost charge related style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman occasioned unused manufacturing capacity nbsp manufacture other product such party manufacturing facility nbsp amortization property plant equipment reasonably related manufacturing licensed compound licensed product hereunder nbsp allocation general corporate overhead other administrative cost expense directly indirectly involved management manufacturing material procurement product distribution licensed compound licensed product style margin margin bottom text indent font size font family time roman with respect manufacturing activity conducted third party such party affiliate fully allocated cost shall consist invoiced cost charge supplier good service directly related such manufacturing activity style margin margin bottom text indent font size font family time roman cover covering covered mean with respect product composition technology process method that absence ownership license granted under valid claim manufacture offer sale sale importation such product composition practice such technology process method would infringe such valid claim case valid claim that issued would infringe such valid claim were issue style margin margin bottom text indent font size font family time roman develop development mean discovery research preclinical development clinical development with respect product including identification characterization optimization clinical testing pharmacology study toxicology study formulation chemical analysis bioanalytical analysis material performance study such measurement stability physical form dissolution visual spectroscopic analysis like manufacturing process development scale including active pharmaceutical ingredient drug product production manufacturing clinical clinical supply foregoing activity quality assurance quality control technical support pharmacokinetic study clinical study interacting with regulatory authority regarding foregoing other activity relating seeking obtaining maintaining regulatory approval such product from other applicable regulatory authority style margin margin bottom text indent font size font family time roman development cost mean with respect development activity performed behalf party hereunder cost expense such party affiliate that paid payable third party specifically associated with conduct such activity clarity development cost shall include internal cost party affiliate with respect development activity including cost with respect employee such party affiliate cost expense kind that normally included full time equivalent rate internal personnel style margin margin bottom text indent font size font family time roman diagnostic know mean know that necessary reasonably useful develop commercialize diagnostic product field territory style margin margin bottom text indent font size font family time roman diagnostic patent mean patent claiming directed diagnostic know style margin margin bottom text indent font size font family time roman diagnostic product mean biomarker diagnostic assay test that designed with that relates associated with correlated with patient population that respond treatment with particular therapeutic product veterinary product applicable style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman dollar mean legal tender style margin margin bottom text indent font size font family time roman eisai collaboration mean eisai collaboration know eisai collaboration patent style margin margin bottom text indent font size font family time roman eisai collaboration know mean know that discovered developed invented conceived reduced practice solely behalf eisai affiliate sublicensees pursuant conduct activity under collaboration exercise eisai license under this agreement from after prior agreement effective date being understood that activity carried behalf epizyme affiliate sublicensees under collaboration shall construed interpreted carried behalf eisai affiliate sublicensees purpose hereof style margin margin bottom text indent font size font family time roman eisai collaboration patent mean patent claiming directed eisai collaboration know style margin margin bottom text indent font size font family time roman eisai mean eisai know eisai patent style margin margin bottom text indent font size font family time roman eisai know mean know that nbsp controlled eisai prior agreement effective date time thereafter prior expiration target exclusivity period nbsp arises outside collaboration nbsp necessary reasonably useful development manufacture commercialization licensed compound licensed product field territory expressly excluding know controlled eisai that relates compound molecule that compound directed purpose clarity eisai know includes diagnostic know controlled eisai prior agreement effective date time thereafter prior expiration target exclusivity period excludes collaboration know owned eisai eisai interest joint know style margin margin bottom text indent font size font family time roman eisai patent mean patent that nbsp controlled eisai prior agreement effective date time thereafter prior expiration target exclusivity period nbsp arise outside collaboration nbsp claim directed eisai know expressly excluding patent that claim directed composition matter compound molecule that compound directed purpose clarity eisai patent include diagnostic patent controlled eisai prior agreement effective date time thereafter prior expiration target exclusivity period exclude collaboration patent owned eisai eisai interest joint patent style margin margin bottom text indent font size font family time roman eisai territory mean japan style margin margin bottom text indent font size font family time roman mean european medicine agency successor entity thereto style margin margin bottom text indent font size font family time roman epizyme collaboration mean epizyme collaboration know epizyme collaboration patent style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman epizyme collaboration know mean know that discovered developed invented conceived reduced practice solely behalf epizyme affiliate sublicensees pursuant conduct activity under collaboration exercise epizyme license under this agreement from after prior agreement effective date being understood that activity carried behalf eisai affiliate sublicensees under this agreement shall construed interpreted carried behalf epizyme affiliate sublicensees purpose hereof style margin margin bottom text indent font size font family time roman epizyme collaboration patent mean patent claiming directed epizyme collaboration know style margin margin bottom text indent font size font family time roman epizyme mean epizyme know epizyme patent style margin margin bottom text indent font size font family time roman epizyme know mean know that nbsp controlled epizyme prior agreement effective date time thereafter prior expiration target exclusivity period nbsp arises outside collaboration nbsp necessary reasonably useful development manufacture commercialization licensed compound licensed product field territory expressly excluding know controlled epizyme that relates compound molecule that compound directed purpose clarity epizyme know includes diagnostic know controlled epizyme prior agreement effective date time thereafter prior expiration target exclusivity period excludes collaboration know owned epizyme epizyme interest joint know style margin margin bottom text indent font size font family time roman epizyme patent mean style margin margin bottom text indent font size font family time roman patent patent application listed exhibit style margin margin bottom text indent font size font family time roman substitution divisionals continuation continuation part provisional application reissue renewal registration confirmation examination extension supplementary protection certificate like patent patent application forth exhibit style margin margin bottom text indent font size font family time roman foreign counterpart foregoing clause nbsp style margin margin bottom text indent font size font family time roman patent other than those included foregoing clause nbsp through nbsp that controlled epizyme prior agreement effective date time thereafter prior expiration target exclusivity period arise outside collaboration that claim directed epizyme know expressly excluding patent that claim directed composition matter compound molecule that compound directed style margin margin bottom text indent font size font family time roman purpose clarity epizyme patent include diagnostic patent controlled epizyme prior agreement effective date time thereafter prior expiration target exclusivity period exclude collaboration patent owned epizyme epizyme interest joint patent style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman epizyme territory mean entire world other than japan style margin margin bottom text indent font size font family time roman mean country that officially recognized member state european union particular time during term style margin margin bottom text indent font size font family time roman executive officer mean epizyme chief executive officer eisai president oncology product creation unit style margin margin bottom text indent font size font family time roman mean catalytic subunit polycomb repressive complex which highly conserved histone methyltransferase that target lysine histone style margin margin bottom text indent font size font family time roman compound mean compound that style margin margin bottom text indent font size font family time roman directed style margin margin bottom text indent font size font family time roman vitro style font size vertical align bottom potency with numerical value selectivity relative next most active target other than style margin margin bottom text indent font size font family time roman mean food drug administration successor entity thereto style margin margin bottom text indent font size font family time roman field mean treatment prevention palliation diagnosis human veterinary disease disorder condition style margin margin bottom text indent font size font family time roman first commercial sale mean with respect each licensed product country epizyme territory eisai territory first sale which revenue been recognized applicable commercialization party affiliate sublicensees consumption general public such licensed product such country after regulatory approval pricing reimbursement approval legally required such sale such licensed product been obtained such country provided however that following shall constitute first commercial sale style margin margin bottom text indent font size font family time roman sale affiliate sublicensee unless affiliate sublicensee last entity distribution chain licensed product style margin margin bottom text indent font size font family time roman such licensed product clinical trial clinical activity other development activity disposal transfer licensed product bona fide charitable purpose style margin margin bottom text indent font size font family time roman treatment sale named patient sale compassionate style margin margin bottom text indent font size font family time roman global development plan mean development plan approved that forth development activity epizyme with respect therapeutic product related diagnostic product such plan amended from time time accordance with term hereof style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman mean then current good laboratory practice standard promulgated endorsed defined part such other comparable regulatory standard jurisdiction outside style margin margin bottom text indent font size font family time roman mean investigational drug application submitted pursuant part title code federal regulation including amendment thereto reference herein shall include extent applicable comparable filing outside investigation product other country group country such clinical trial application style margin margin bottom text indent font size font family time roman indication mean human disease condition sign symptom human disease condition style margin margin bottom text indent font size font family time roman initiate initiation mean with respect clinical trial first dosing first subject enrolled such clinical trial with therapeutic product style margin margin bottom text indent font size font family time roman japan development plan mean development plan approved that forth japan specific development activity eisai with respect therapeutic product such plan amended from time time accordance with term hereof style margin margin bottom text indent font size font family time roman japan specific development activity mean with respect licensed product such development activity primary purpose which obtain maintain regulatory approval such licensed product japan style margin margin bottom text indent font size font family time roman joint mean joint know joint patent style margin margin bottom text indent font size font family time roman joint know mean know that jointly discovered developed invented conceived reduced practice more employee agent consultant epizyme affiliate sublicensees hand more employee agent consultant eisai affiliate sublicensees other hand pursuant conduct activity under collaboration exercise each party license under this agreement from after prior agreement effective date style margin margin bottom text indent font size font family time roman joint patent mean patent that claim directed joint know style margin margin bottom text indent font size font family time roman font style white space nowrap know font mean tangible intangible style margin margin bottom text indent font size font family time roman information technique technology practice trade secret invention whether patentable method knowledge know skill experience data result including pharmacological toxicological clinical clinical test data result research data report batch record analytical quality control data analytical method including applicable reference standard full batch documentation packaging record release stability storage shelf life data manufacturing process information result description software algorithm style margin margin bottom text indent font size font family time roman composition matter cell cell line assay animal model physical biological chemical material style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman each case that generally known style margin margin bottom text indent font size font family time roman used this agreement clinical test data shall deemed include information related clinical testing including patient report form investigator report biostatistical pharmaco economic other related analysis regulatory filing communication like style margin margin bottom text indent font size font family time roman mean applicable statute rule regulation order judgment ordinance having effect federal national multinational state provincial county city other political subdivision style margin margin bottom text indent font size font family time roman licensed compound mean compound that style margin margin bottom text indent font size font family time roman synthesized identified either party respective affiliate third party working with behalf such party respective affiliate jointly behalf party conduct collaboration exercise such party license under this agreement from after prior agreement effective date excluding compound controlled either party first identified compound after expiration target exclusivity period style margin margin bottom text indent font size font family time roman otherwise controlled epizyme prior agreement effective date time thereafter prior expiration target exclusivity period style margin margin bottom text indent font size font family time roman licensed product mean therapeutic product diagnostic product veterinary product applicable style margin margin bottom text indent font size font family time roman mean regulatory application filed with mhlw seeking regulatory approval licensed product amendment supplement thereto filed with mhlw style margin margin bottom text indent font size font family time roman major country mean following country france germany italy spain united kingdom major country mean foregoing country style margin margin bottom text indent font size font family time roman major market country mean nbsp united state nbsp japan nbsp more major country style margin margin bottom text indent font size font family time roman manufacture manufacturing mean applicable activity associated with production manufacture supply processing filling packaging labeling shipping storage licensed compound licensed product component thereof including manufacturing process formulation development scale including active pharmaceutical ingredient drug production manufacturing process validation stability testing preclinical clinical commercial manufacture analytical development product characterization quality assurance quality control development testing release style margin margin bottom text indent font size font family time roman mhlw mean ministry health labour welfare japan pharmaceutical medical device agency successor either them case style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman mean drug application more fully described successor regulation amendment supplement thereto filed with equivalent filing including country regulatory jurisdiction other than united state style margin margin bottom text indent font size font family time roman sale mean with respect licensed product period gross amount invoiced applicable commercialization party affiliate sublicensees each selling party third party customer sale such licensed product during such period following deduction actually incurred allowed paid accrued specifically allocated financial statement accordance with gaap style margin margin bottom text indent font size font family time roman customary reasonable trade quantity cash discount wholesaler allowance inventory management style margin margin bottom text indent font size font family time roman customary reasonable credit rebate chargebacks including those managed care entity government agency allowance credit customer account rejection return including wholesaler retailer return account retroactive price reduction affecting such licensed product style margin margin bottom text indent font size font family time roman freight postage duty transportation charge relating such licensed product including handling insurance therefor style margin margin bottom text indent font size font family time roman sale such equivalent excise other consumption custom duty excluding paid income from such sale extent selling party otherwise entitled credit refund such duty payment made style margin margin bottom text indent font size font family time roman amount previously included sale that written selling party uncollectible accordance with standard practice such selling party writing uncollectible amount consistently applied provided however that such written amount subsequently collected such collected amount shall included sale period which they subsequently collected style margin margin bottom text indent font size font family time roman monetary consideration received licensed product country sale will calculated based average price charged such licensed product such country during preceding calendar quarter absence such sale fair market value licensed product such country determined party good faith party unable reach such agreement party will refer such matter jointly selected third party with expertise pricing pharmaceutical product that employee consultant legal advisor officer director stockholder have conflict interest with respect either party resolution party unable agree such third party expert within thirty after party notified other party that desire refer such matter such third party resolution either party request that york york office american arbitration association appoint such expert resolve such matter resolution determined such expert that either jointly selected appointed shall final binding party notwithstanding anything contrary herein transfer disposal licensed product without style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman consideration marketing regulatory development charitable purpose such sampling clinical trial preclinical trial compassionate named patient indigent patient program shall deemed sale hereunder style margin margin bottom text indent font size font family time roman sale shall determined only first sale party affiliate sublicensees font style white space nowrap sublicensee font third party style margin margin bottom text indent font size font family time roman each party shall shall cause selling party licensed product loss leader otherwise unfairly inappropriately discount gross invoiced sale price licensed product manner that intended benefit provide incentive enhance sale other pharmaceutical product sold such party selling party sale licensed product between party selling party resale shall excluded from computation sale subsequent resale such licensed product font style white space nowrap sublicensee font third party shall included within computation sale addition sale licensed product party affiliate sublicensees other party affiliate sublicensees pursuant mutually agreed manufacturing supply relationship shall excluded from computation sale subsequent resale such licensed product purchasing party affiliate sublicensee font style white space nowrap sublicensee font third party shall included within computation sale style margin margin bottom text indent font size font family time roman therapeutic product sold part combination product defined below country sale such country period will product nbsp sale combination product calculated above such country such period calculated combination product nbsp fraction where style margin margin bottom text indent font size font family time roman average wholesale acquisition cost such country therapeutic product comprising licensed compound sole therapeutically active ingredient during such period style margin margin bottom text indent font size font family time roman average wholesale acquisition cost such country other therapeutically active ingredient contained combination product when sold separately during such period style margin margin bottom text indent font size font family time roman determined reference combination product sale described above then sale purpose determining royalty payment will calculated above average wholesale acquisition cost above equation shall determined mutual agreement reached good faith party prior accounting period question based equitable method determining same that take into account applicable country variation dosage unit relative fair market value each therapeutically active ingredient combination product party unable reach such agreement prior applicable accounting period then party will refer such matter jointly selected third party with expertise pricing pharmaceutical product that employee consultant legal advisor officer director stockholder have conflict interest with respect either party resolution party unable agree such third party expert within thirty after party notified other party that desire refer such matter such third party resolution either party request that york york office appoint such expert resolve such matter resolution determined such expert that either jointly selected appointed shall final binding party style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman used this section nbsp combination product mean therapeutic product that contains more additional active ingredient whether coformulated copackaged that licensed compound pharmaceutical dosage form vehicle adjuvant excipients shall deemed active ingredient style margin margin bottom text indent font size font family time roman patent mean nbsp national regional international patent patent application including provisional patent application nbsp patent application filed either from such patent patent application provisional application from application claiming priority from either these including divisionals continuation continuation part provisionals converted provisionals continued prosecution application nbsp patent that have issued future issue from foregoing patent application including utility model petty patent design patent certificate invention nbsp extension restoration existing future extension restoration mechanism including revalidations reissue examination extension including supplementary protection certificate like foregoing patent patent application nbsp similar right including called pipeline protection importation revalidation confirmation introduction patent registration patent patent addition such foregoing patent application patent style margin margin bottom text indent font size font family time roman patent based exclusivity mean with respect licensed product country territory that least valid claim epizyme patent eisai patent that cover composition matter applicable licensed compound collaboration patent joint patent cover such licensed product such country style margin margin bottom text indent font size font family time roman person mean individual partnership joint venture limited liability company corporation firm trust association unincorporated organization governmental authority agency other entity specifically listed herein style margin margin bottom text indent font size font family time roman phase clinical trial mean human clinical trial product country principal purpose which preliminary determination safety healthy individual patient that would satisfy requirement similar clinical study prescribed relevant regulatory authority country other than united state style margin margin bottom text indent font size font family time roman phase clinical trial mean human clinical trial product country that would satisfy requirement intended explore variety dose response duration effect generate initial evidence clinical safety activity target patient population similar clinical study prescribed relevant regulatory authority country other than united state style margin margin bottom text indent font size font family time roman phase clinical trial mean human clinical trial product country that would satisfy requirement intended nbsp establish that product safe efficacious intended nbsp define warning precaution adverse reaction that associated with product dosage range prescribed nbsp support regulatory approval such product style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman prosecution maintenance prosecute maintain mean with regard patent preparation filing prosecution maintenance such patent well examination reissue appeal request patent term adjustment with respect such patent together with initiation defense interference initiation defense opposition other similar proceeding with respect particular patent appeal therefrom clarification prosecution maintenance prosecute maintain shall include other defense enforcement action taken with respect patent style margin margin bottom text indent font size font family time roman mean priority review voucher awarded pursuant section nbsp section nbsp ffdca style margin margin bottom text indent font size font family time roman regulatory approval mean with respect country territory approval license authorization applicable regulatory authority necessary marketing sale pharmaceutical product particular indication such country territory excluding separate pricing reimbursement approval that required style margin margin bottom text indent font size font family time roman regulatory authority mean with respect country territory national regional state local regulatory agency department bureau commission council other governmental entity that regulates otherwise exercise authority with respect development manufacture marketing sale distribution other exploitation pharmaceutical product such country including mhlw successor thereto style margin margin bottom text indent font size font family time roman regulatory based exclusivity mean with respect licensed product country territory that nbsp applicable commercialization party affiliate sublicensees been granted exclusive legal right regulatory authority otherwise entitled exclusive legal right operation such country market sell licensed product active ingredient comprising such licensed product such country nbsp data information submitted applicable commercialization party affiliate sublicensees relevant regulatory authority such country purpose obtaining regulatory approval disclosed referenced relied upon such regulatory authority including relying upon regulatory authority previous finding regarding safety effectiveness licensed product support regulatory approval marketing product third party such country style margin margin bottom text indent font size font family time roman regulatory dossier mean technical medical scientific registration authorization approval including approval ndas supplement amendment post approval pricing third party reimbursement approval labeling approval regulatory authority necessary development including conduct clinical study manufacture distribution marketing promotion offer sale import reimbursement export sale product regulatory jurisdiction together with related correspondence from regulatory authority document referenced complete regulatory chronology each including regulatory material drug master file style margin margin bottom text indent font size font family time roman regulatory material mean regulatory application notification registration regulatory approval other submission made with regulatory authority that style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman necessary reasonably desirable order develop manufacture market sell otherwise commercialize product particular country territory possession regulatory material include inds ctas ndas maas amendment supplement foregoing application pricing approval style margin margin bottom text indent font size font family time roman mean country world other than japan style margin margin bottom text indent font size font family time roman sublicensee mean nbsp third party whom applicable commercialization party granted license sublicense pursuant section nbsp section nbsp develop commercialize licensed compound licensed product field excluding third party acting solely distributor nbsp with respect epizyme third party whom epizyme granted license under epizyme epizyme collaboration epizyme interest joint develop commercialize licensed compound licensed product field epizyme territory excluding third party acting solely distributor style margin margin bottom text indent font size font family time roman target exclusivity period mean period commencing prior agreement effective date ending date that eight year after first commercial sale licensed product first country territory style margin margin bottom text indent font size font family time roman territory mean epizyme territory eisai territory collectively style margin margin bottom text indent font size font family time roman therapeutic product mean human therapeutic prophylactic palliative pharmaceutical product comprising licensed compound whether sole active ingredient dosage form formulation style margin margin bottom text indent font size font family time roman third party mean person other than epizyme eisai that affiliate epizyme eisai style margin margin bottom text indent font size font family time roman mean university north carolina chapel hill style margin margin bottom text indent font size font family time roman license agreement mean license agreement dated january nbsp between epizyme style margin margin bottom text indent font size font family time roman united state mean united state america territory possession style margin margin bottom text indent font size font family time roman valid claim mean style margin margin bottom text indent font size font family time roman claim issued patent jurisdiction outside that expired lapsed been cancelled abandoned been dedicated public disclaimed held unenforceable invalid cancelled court administrative agency competent jurisdiction order decision from which appeal been taken including through opposition reexamination reissue disclaimer style margin margin bottom text indent font size font family time roman claim pending patent application that been finally abandoned finally rejected which been pending more than year from date filing earliest priority patent application which such pending patent application entitled claim benefit style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman clarity claim issued patent that ceased valid claim before issued because been pending long subsequently issued otherwise described clause nbsp foregoing sentence shall again considered valid claim once issue same principle shall apply similar circumstance such example without limitation final rejection claim overcome style margin margin bottom text indent font size font family time roman veterinary product mean therapeutic prophylactic palliative pharmaceutical product comprising licensed compound whether sole active ingredient veterinary dosage form formulation style margin margin bottom text indent font size font family time roman additional definition each following definition forth section this agreement indicated below style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman definition valign bottom nbsp nbsp valign bottom nowrap style border bottom solid width font size font family time roman section style font family time roman font size valign valign bottom nbsp nbsp valign style font family time roman font size valign alliance manager valign bottom nbsp nbsp valign style font family time roman font size valign amended letter agreement valign bottom nbsp nbsp valign recital style font family time roman font size valign arbitration request valign bottom nbsp nbsp valign style font family time roman font size valign breaching party valign bottom nbsp nbsp valign style font family time roman font size valign chairperson valign bottom nbsp nbsp valign style font family time roman font size valign collaboration valign bottom nbsp nbsp valign style font family time roman font size valign combination product valign bottom nbsp nbsp valign style font family time roman font size valign competing business valign bottom nbsp nbsp valign style font family time roman font size valign competitive infringement valign bottom nbsp nbsp valign style font family time roman font size valign compulsory third party product valign bottom nbsp nbsp valign style font family time roman font size valign confidential information valign bottom nbsp nbsp valign style font family time roman font size valign create valign bottom nbsp nbsp valign style font family time roman font size valign valign bottom nbsp nbsp valign style font family time roman font size valign disclosing party valign bottom nbsp nbsp valign style font family time roman font size valign eisai valign bottom nbsp nbsp valign preamble style font family time roman font size valign eisai patent challenge valign bottom nbsp nbsp valign style font family time roman font size valign epizyme valign bottom nbsp nbsp valign preamble style font family time roman font size valign excess eisai value valign bottom nbsp nbsp valign style font family time roman font size valign existing confidentiality agreement valign bottom nbsp nbsp valign style font family time roman font size valign existing know valign bottom nbsp nbsp valign style font family time roman font size valign existing patent valign bottom nbsp nbsp valign style font family time roman font size valign existing agreement valign bottom nbsp nbsp valign recital style font family time roman font size valign ffdca valign bottom nbsp nbsp valign style font family time roman font size valign gaap valign bottom nbsp nbsp valign style font family time roman font size valign valign bottom nbsp nbsp valign recital style font family time roman font size valign indemnified party valign bottom nbsp nbsp valign style font family time roman font size valign indemnifying party valign bottom nbsp nbsp valign style font family time roman font size valign valign bottom nbsp nbsp valign style font family time roman font size valign employee valign bottom nbsp nbsp valign table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman definition valign bottom nbsp nbsp valign bottom nowrap style border bottom solid width font size font family time roman section style font family time roman font size valign loss valign bottom nbsp nbsp valign style font family time roman font size valign marketing related material valign bottom nbsp nbsp valign style font family time roman font size valign negotiating period valign bottom nbsp nbsp valign style font family time roman font size valign breaching party valign bottom nbsp nbsp valign style font family time roman font size valign party party valign bottom nbsp nbsp valign preamble style font family time roman font size valign payee valign bottom nbsp nbsp valign style font family time roman font size valign payor valign bottom nbsp nbsp valign style font family time roman font size valign prior agreement valign bottom nbsp nbsp valign recital style font family time roman font size valign prior agreement effective date valign bottom nbsp nbsp valign recital style font family time roman font size valign product information valign bottom nbsp nbsp valign style font family time roman font size valign valign bottom nbsp nbsp valign style font family time roman font size valign receiving party valign bottom nbsp nbsp valign style font family time roman font size valign redemption date valign bottom nbsp nbsp valign style font family time roman font size valign royalty term valign bottom nbsp nbsp valign style font family time roman font size valign sdea valign bottom nbsp nbsp valign style font family time roman font size valign selling party valign bottom nbsp nbsp valign style font family time roman font size valign severed clause valign bottom nbsp nbsp valign style font family time roman font size valign subcommittee valign bottom nbsp nbsp valign style font family time roman font size valign term valign bottom nbsp nbsp valign style font family time roman font size valign third party claim valign bottom nbsp nbsp valign style font family time roman font size valign third party offer notice valign bottom nbsp nbsp valign table style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center collaboration overview development activity style margin margin bottom text indent font size font family time roman collaboration overview pursuant this agreement party have collaborated conduct global development activity prior restatement date after restatement date epizyme shall continue conduct global development activity with respect licensed compound licensed product shall commercialize licensed product epizyme territory eisai shall conduct japan specific development activity with respect licensed compound licensed product shall commercialize licensed product eisai territory collaboration style margin margin bottom text indent font size font family time roman development activity style margin margin bottom text indent font size font family time roman subject eisai sole right responsibility conduct japan specific development activity forth section nbsp epizyme shall have sole right responsibility global development activity licensed product following restatement date epizyme shall commercially reasonable effort conduct such global development activity accordance with global development plan style margin margin bottom text indent font size font family time roman later than after restatement date epizyme shall provide proposed global development plan review approval pursuant section nbsp style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman eisai shall have sole right responsibility japan specific development activity licensed product following restatement date eisai shall commercially reasonable effort conduct such japan specific development activity accordance with japan development plan style margin margin bottom text indent font size font family time roman prior commencement japan specific development activity eisai shall provide proposed japan development plan review approval pursuant section nbsp style margin margin bottom text indent font size font family time roman epizyme shall submit review approval proposed amendment global development plan eisai shall submit review approval proposed amendment japan development plan style margin margin bottom text indent font size font family time roman report result each party shall provide other party quarterly written progress report status development activity under collaboration including summary data result associated with such development activity with respect epizyme progress toward completing milestone section nbsp hereof least five business advance each meeting style margin margin bottom text indent font size font family time roman subcontracting subject term this agreement each party shall have right engage affiliate third party subcontractor perform obligation under this agreement affiliate subcontractor engaged party perform party obligation forth this agreement shall meet qualification typically required such party performance work similar scope complexity subcontracted activity provided that party engaging affiliate subcontractor hereunder shall remain responsible obligated such activity style margin margin bottom text indent font size font family time roman regulatory matter compliance style margin margin bottom text indent font size font family time roman compliance each party agrees that performing obligation under this agreement shall perform such obligation good scientific manner comply material respect with applicable other applicable current international regulatory requirement standard including applicable cgmp good clinical practice comparable foreign regulatory standard other style margin margin bottom text indent font size font family time roman data integrity each party shall maintain cause maintained record development activity pursuant this agreement accordance with sufficient detail accuracy good scientific manner appropriate patent regulatory purpose properly reflecting work done result achieved performance development activity such record shall retained each party least three year after termination this agreement such longer period required each party shall have right during normal business hour upon reasonable notice inspect copy such record except extent that party reasonably determines that such record contain confidential information that licensed other party which other party otherwise have right hereunder style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman regulatory filing data epizyme sole cost shall have right responsibility consultation with eisai preparing filing maintaining regulatory filing regulatory approval necessary development commercialization licensed compound licensed product field epizyme territory including applicable inds ndas epizyme shall such regulatory filing regulatory approval relating epizyme territory eisai sole cost shall have right responsibility consultation with epizyme preparing filing maintaining regulatory filing regulatory approval necessary japan specific development activity commercialization licensed compound licensed product field eisai territory including applicable inds ndas eisai shall such regulatory filing regulatory approval relating eisai territory style margin margin bottom text indent font size font family time roman adverse event reporting global safety database epizyme sole cost shall solely responsible reporting applicable regulatory authority epizyme territory adverse drug experience associated with licensed compound licensed product field eisai sole cost shall solely responsible reporting applicable regulatory authority eisai territory adverse drug experience associated with licensed compound licensed product field party shall negotiate agree within ninety following restatement date detailed safety data exchange agreement sdea setting forth reasonable customary procedure governing collection investigation reporting exchange information enable collaboration matter safety licensed compound licensed product worldwide including exchange adverse drug experience information similar matter sufficient permit each party comply with reporting obligation under this section nbsp epizyme sole cost shall establish hold maintain global pharmacovigilance database licensed compound licensed product eisai shall transfer safety data possession restatement date epizyme accordance with section nbsp style margin margin bottom text indent font size font family time roman transition matter style margin margin bottom text indent font size font family time roman following restatement date party shall commercially reasonable effort perform transfer other transitional activity forth exhibit timeline therefor specified exhibit style margin margin bottom text indent font size font family time roman epizyme shall reimburse eisai quarterly basis nbsp internal cost including cost with respect employee eisai affiliate that incurred eisai affiliate performance transfer other transitional activity forth exhibit solely extent such internal cost specifically identified under cost associated column exhibit nbsp reasonable documented cost that paid payable third party incurred eisai affiliate performance transfer other transitional activity forth exhibit solely extent such cost paid payable third party specifically identified under cost associated column exhibit with respect transfer transitional activity which forth exhibit which epizyme request eisai agrees perform internal cost including cost with respect employee eisai affiliate reasonable documented cost that paid payable third party incurred eisai affiliate such performance provided that case foregoing clause nbsp cost style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman shall only reimbursed epizyme approved such payment writing internal cost shall payable full time equivalent rate month part approval epizyme pursuant foregoing clause eisai shall provide epizyme good faith estimate internal cost will incur prior performing applicable transfer transition activity avoidance doubt eisai shall obligated agree perform transfer transitional activity requested epizyme under foregoing clause following each calendar quarter which such cost incurred eisai shall provide epizyme with written report invoice setting forth reasonable detail such cost incurred during quarter epizyme shall invoice within thirty invoice date eisai shall keep shall require affiliate keep full clear accurate book record cost incurred eisai affiliate which reimbursement requested under this section nbsp period least three year following applicable quarter epizyme shall have right audit such book record pursuant term section applied this section nbsp mutatis mutandis style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center commercialization activity diligence manufacturing supply style margin margin bottom text indent font size font family time roman commercialization licensed compound licensed compound basis nbsp epizyme sole cost either itself through affiliate sublicensees contractor shall have sole right responsibility commercialization activity connection with such licensed compound therapeutic product veterinary product comprising such licensed compound related diagnostic product field epizyme territory nbsp eisai sole cost either itself through affiliate sublicensees contractor shall have sole right responsibility commercialization activity connection with such licensed compound therapeutic product veterinary product comprising such licensed compound related diagnostic product field eisai territory epizyme shall book sale licensed product epizyme territory eisai shall book sale licensed product eisai territory style margin margin bottom text indent font size font family time roman diligence style margin margin bottom text indent font size font family time roman epizyme shall commercially reasonable effort itself through affiliate sublicensee develop obtain regulatory approval commercialize least each united state major country clarity epizyme shall have obligation commercially reasonable effort develop obtain regulatory approval commercialize more than country outside united state major country style margin margin bottom text indent font size font family time roman eisai shall commercially reasonable effort itself through affiliate sublicensee conduct japan specific development activity obtain regulatory approval commercialize least japan provided that epizyme conduct such global development activity excluding japan specific development activity necessary submit application regulatory style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman approval least japan epizyme comply with obligation under section nbsp supply agreement contemplated thereby then eisai shall duration epizyme noncompliance excused from obligation under this section nbsp extent conduct such global development activity such compliance epizyme reasonably necessary eisai satisfy obligation under this section nbsp clarity eisai shall have obligation commercially reasonable effort conduct japan specific development activity obtain regulatory approval commercialize more than japan style margin margin bottom text indent font size font family time roman subject foregoing obligation commercially reasonable effort neither party provides representation warranty guarantee that collaboration will successful that particular result will achieved with respect collaboration compound licensed compound licensed product hereunder style margin margin bottom text indent font size font family time roman manufacturing supply style margin margin bottom text indent font size font family time roman subject term condition this section nbsp epizyme shall responsible manufacture supply licensed compound licensed product including active pharmaceutical ingredient thereof development commercialization purpose epizyme epizyme territory unless eisai elect undertake such manufacture supply forth section nbsp eisai eisai territory during term style margin margin bottom text indent font size font family time roman eisai shall have right obligation elect itself manufacture supply have manufactured supplied licensed compound licensed product japan specific development activity commercialization purpose eisai eisai territory during term upon written notice epizyme such election provided that such notice provided after date that prior projected date reasonably determined eisai first filing licensed product eisai territory then nbsp unless otherwise agreed party eisai shall continue purchase from epizyme requirement licensed compound licensed product period following such notice date unless epizyme fails supply such requirement licensed compound licensed product required under section nbsp supply agreement contemplated thereby nbsp eisai shall reimburse epizyme eisai territory specific cost expense incurred epizyme attributable manufacture supply licensed compound licensed product eisai recovered through transfer pricing amount paid eisai epizyme prior such transition such example cost incurred meeting regulatory requirement relating eisai territory translation cost style margin margin bottom text indent font size font family time roman upon written request either party party shall good faith negotiate enter into clinical supply agreement pursuant which epizyme would manufacture supply eisai such quantity licensed compound licensed product shall reasonably requested eisai writing order conduct japan specific development activity such clinical supply agreement shall nbsp provide that epizyme shall manufacture such licensed compound licensed product accordance with cgmp other eisai territory applicable specification therefor shall deliver style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman such licensed compound licensed product eisai incoterms epizyme contract manufacturer manufacturing facility nbsp provide that eisai shall epizyme purchase price equal each such delivery licensed compound licensed product nbsp provide that epizyme shall invoice eisai applicable purchase price promptly after delivery eisai shall such invoice later than forty five after receipt thereof nbsp contain other reasonable customary clinical supply term including provision addressing forecasting ordering delivery payment acceptance rejection procedure regulatory assistance warranty indemnification limitation liability quality assurance control style margin margin bottom text indent font size font family time roman subject eisai right make election forth section nbsp later than year prior projected date reasonably determined eisai receipt first regulatory approval licensed product eisai territory party shall good faith negotiate enter into commercial supply agreement pursuant which epizyme shall manufacture supply eisai commercial quantity finished packaged licensed product sale distribution eisai territory such commercial supply agreement shall nbsp provide that purchase price licensed product supplied thereunder shall equal percent epizyme cost good therefor nbsp contain other reasonable customary commercial supply term including provision addressing forecasting ordering delivery payment acceptance rejection procedure regulatory assistance warranty indemnification limitation liability quality assurance control style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center governance style margin margin bottom text indent font size font family time roman joint steering committee party have restatement date established joint steering committee more fully described this section nbsp shall have review oversight decision making responsibility more specifically provided herein each party agrees keep informed progress activity under collaboration establish subcommittee forth section nbsp style margin margin bottom text indent font size font family time roman membership shall comprised three representative such other number representative party agree from each eisai epizyme each party replace representative time upon written notice other party each representative party shall have sufficient seniority expertise biotechnology pharmaceutical industry participate member designate substitute attend perform function that member meeting provided that such substitute meet foregoing qualification each party subject other party prior approval invite member representative such party attend meeting voting participant subject confidentiality obligation article epizyme shall designate chairperson chairperson oversee operation style margin margin bottom text indent font size font family time roman meeting style margin margin bottom text indent font size font family time roman shall meet least twice each calendar year more frequently party mutually deem appropriate such date such place time style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman provided herein party shall agree member attend meeting either person telephone video conference similar mean which each participant hear what said heard other participant provided that least meeting calendar year shall held person style margin margin bottom text indent font size font family time roman meeting that held person shall alternate between office party such other location party agree with first meeting after restatement date held office epizyme member also convene polled consulted from time time electronic mail correspondence deemed necessary appropriate quorum shall exist whenever there present meeting least representative appointed each party each party will bear expense incurs regard participating meeting including travel living expense style margin margin bottom text indent font size font family time roman minute alliance manager from party alternating basis shall responsible preparing circulating minute each meeting setting forth inter alia overview discussion meeting list action decision determination approved such minute shall effective only after approval both party writing which electronic mail definitive minute meeting shall finalized later than thirty after meeting which minute pertain style margin margin bottom text indent font size font family time roman responsibility shall perform following function style margin margin bottom text indent font size font family time roman review monitor progress collaboration style margin margin bottom text indent font size font family time roman review approve initial global development plan amendment thereto style margin margin bottom text indent font size font family time roman review approve initial japan development plan amendment thereto style margin margin bottom text indent font size font family time roman serve forum exchange information facilitate discussion regarding conduct collaboration hereunder style margin margin bottom text indent font size font family time roman attempt resolve dispute subcommittee style margin margin bottom text indent font size font family time roman such other responsibility assigned pursuant this agreement mutually agreed upon party from time time style margin margin bottom font size font family time roman each party shall retain right power discretion granted under this agreement such right power discretion shall delegated vested unless such delegation vesting right expressly provided this agreement party expressly agree writing clarity shall have authority beyond specific matter forth this section nbsp particular shall have power amend modify term this agreement case where matter within authority arises shall convene meeting consider such matter within thirty after matter first brought attention earlier next regularly scheduled meeting style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman decision except otherwise provided herein decision shall made consensus with each party collectively having vote party shall good faith reasonable effort attempt reach consensus each matter submitted agree matter within authority within business after attempted reach such decision then nbsp eisai shall have right determine resolution such matter relating japan development plan japan specific development activity regulatory commercialization issue eisai territory extent eisai assumed manufacturing responsibility eisai territory accordance with section nbsp manufacturing issue relating eisai territory sole discretion nbsp epizyme shall have right determine resolution other matter including matter relating global development plan global development manufacturing regulatory commercialization issue sole discretion style margin margin bottom text indent font size font family time roman subcommittee from time time establish subcommittee oversee particular project activity deems necessary advisable each subcommittee each subcommittee shall consist such number member determines appropriate from time time such member shall individual with expertise responsibility relevant area such clinical development pharmacology clinical development patent process science manufacturing quality regulatory affair applicable stage project activity style margin margin bottom text indent font size font family time roman alliance manager each party appointed individual alliance manager such party each alliance manager alliance manager shall primary point contact party regarding activity contemplated this agreement shall facilitate such activity hereunder alliance manager shall attend meeting shall responsible assisting performing oversight responsibility name contact information alliance manager replacement chosen epizyme eisai their sole discretion from time time shall promptly provided other party accordance with section nbsp style margin margin bottom text indent font size font family time roman senior management meeting without limiting generality foregoing this article senior management each party including epizyme chief executive officer chief scientific officer chief development officer other appropriate member senior management epizyme designated epizyme eisai president oncology product creation unit other appropriate member senior management eisai designated eisai shall meet person once year time location mutually agreed party discus collaboration strategic plan licensed product other related matter style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center license grant style margin margin bottom text indent font size font family time roman license grant eisai subject term condition this agreement style margin margin bottom text indent font size font family time roman licensed compound licensed product epizyme hereby grant eisai nbsp exclusive right license even epizyme affiliate with right grant sublicenses subject section nbsp under epizyme epizyme style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman collaboration epizyme interest joint obtain maintain regulatory approval offer sale sell import otherwise commercialize excluding manufacturing licensed compound licensed product field eisai territory nbsp exclusive right license with right grant sublicenses subject section nbsp under epizyme epizyme collaboration epizyme interest joint conduct have conducted japan specific development activity eisai elect assume manufacturing responsibility forth section nbsp manufacture have manufactured licensed compound licensed product anywhere world solely purpose exercising right license granted foregoing clause style margin margin bottom text indent font size font family time roman eisai sublicensing right eisai shall have right grant sublicenses under right granted under section nbsp without prior written consent epizyme nbsp eisai affiliate nbsp third party eisai shall provide epizyme with fully executed copy agreement redacted necessary protect confidential commercially sensitive information reflecting sublicense granted eisai under this section nbsp other than sublicenses affiliate third party service provider engaged eisai ordinary course business promptly event later than after execution thereof each sublicense granted eisai under this section nbsp shall subject consistent with term condition this agreement eisai shall remain primarily liable shall guarantee performance affiliate sublicensees with respect sublicense granted pursuant this section nbsp style margin margin bottom text indent font size font family time roman marketing material epizyme hereby grant eisai exclusive right license with right grant sublicenses subject section nbsp solely eisai territory reproduce distribute display modify exploit directly indirectly promotional material used epizyme promotion licensed product epizyme territory solely purpose exercising right license granted section nbsp provided that nbsp neither eisai affiliate sublicensees shall have right license reproduce distribute display modify exploit corporate name logo epizyme affiliate such material nbsp eisai shall solely bear cost expense incurred connection with exercising right under such license nbsp eisai shall solely responsible compliance such promotional material their behalf eisai with eisai territory style margin margin bottom text indent font size font family time roman license grant epizyme subject term condition this agreement style margin margin bottom text indent font size font family time roman licensed compound licensed product eisai hereby grant epizyme nbsp exclusive right license even eisai affiliate with right grant sublicenses subject section nbsp under eisai eisai collaboration eisai interest joint obtain maintain regulatory approval offer sale sell import otherwise commercialize excluding manufacturing licensed compound licensed product field epizyme territory nbsp exclusive right license with right grant sublicenses subject section nbsp under eisai eisai collaboration eisai interest joint conduct have conducted global development activity manufacture have manufactured licensed compound licensed product anywhere world solely purpose exercising style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman right license granted foregoing clause nbsp exclusive right license with right grant sublicenses subject section nbsp under eisai eisai collaboration eisai interest joint manufacture have manufactured licensed compound licensed product anywhere world solely supply thereof eisai eisai territory forth section nbsp style margin margin bottom text indent font size font family time roman epizyme sublicensing right epizyme grant sublicenses under right granted under section nbsp nbsp epizyme affiliate third party country other than country asia without prior written consent eisai nbsp subject compliance with section nbsp epizyme affiliate third party asia outside eisai territory without prior written consent eisai epizyme shall provide eisai with fully executed copy agreement redacted necessary protect confidential commercially sensitive information reflecting sublicense granted epizyme under this section nbsp other than sublicenses affiliate third party service provider engaged epizyme ordinary course business promptly event later than after execution thereof each sublicense granted epizyme under this section nbsp shall subject consistent with term condition this agreement epizyme shall remain primarily liable shall guarantee performance affiliate sublicensees with respect sublicense granted pursuant this section nbsp style margin margin bottom text indent font size font family time roman right retained party style margin margin bottom text indent font size font family time roman right epizyme eisai case expressly granted other party pursuant this agreement shall retained such party style margin margin bottom text indent font size font family time roman clarity subject section nbsp section nbsp style margin margin bottom text indent font size font family time roman epizyme retains right under patent know controlled epizyme including interest joint perform ongoing platform discovery activity style margin margin bottom text indent font size font family time roman epizyme retains right under patent know controlled epizyme including interest joint develop manufacture commercialize biomarkers diagnostic assay test outside this agreement subject license granted eisai under section nbsp style margin margin bottom text indent font size font family time roman eisai retains right under patent know controlled eisai including interest joint develop manufacture commercialize biomarkers diagnostic assay test outside this agreement subject license granted epizyme under section nbsp style margin margin bottom text indent font size font family time roman section nbsp bankruptcy code right license granted under pursuant this agreement eisai epizyme shall otherwise deemed purpose section nbsp bankruptcy code analogous provision other country jurisdiction license right intellectual property defined under section nbsp bankruptcy code party agree that party licensee such right under this agreement shall retain fully exercise their respective right style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman election under bankruptcy code analogous provision other country jurisdiction party further agree that event commencement bankruptcy proceeding against either party under bankruptcy code analogous provision other country jurisdiction party hereto that party such proceeding shall entitled complete duplicate complete access appropriate such intellectual property embodiment such intellectual property which already subject party possession shall promptly delivered nbsp upon such commencement bankruptcy proceeding upon subject party written request therefor unless party subject such proceeding elect continue perform obligation under this agreement nbsp delivered under clause nbsp above following rejection this agreement behalf party subject such proceeding upon written request therefor subject party style margin margin bottom text indent font size font family time roman access know style margin margin bottom text indent font size font family time roman extent already provided prior restatement date each party promptly shall provide other party access copy document material containing know collaboration know licensed other party hereunder shall reasonably requested other party necessary reasonably useful exercise right under license grant section order exercise such license right style margin margin bottom text indent font size font family time roman furtherance subject foregoing without expanding scope license granted pursuant section from time time each party shall style margin margin bottom text indent font size font family time roman make reasonably available other party then existing documentation controlled providing party constituting material support performance advice shop practice standard operating procedure specification material used control method that necessary reasonably useful practice know patent licensed hereunder style margin margin bottom text indent font size font family time roman cause appropriate employee representative such party affiliate meet with employee representative other party mutually convenient time provide reasonable technical assistance other party with respect practice know patent licensed hereunder style margin margin bottom text indent font size font family time roman right negotiation event that epizyme affiliate desire grant third party right develop commercialize including right distribute licensed compound licensed product country asia then epizyme shall provide eisai with written notice third party offer notice that epizyme soliciting offer from third party such right epizyme shall enter into agreement with respect such right with third party until thirty such longer period party agree after delivery third party offer notice eisai within such thirty such longer period party agree period eisai delivers epizyme written offer proposing financial other term expansion this agreement include such right then epizyme shall negotiate such offer with eisai exclusively good faith period style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman ninety such longer period party agree negotiating period epizyme shall discus enter into agreement with respect such right with third party during negotiating period party reach written agreement expansion right under this agreement during negotiating period then epizyme affiliate thereafter shall free enter into agreement with third party with respect such right such term epizyme determine sole discretion eisai fails provide epizyme with written offer proposing financial other term expansion this agreement include such right during applicable thirty such longer period party agree then epizyme affiliate shall free enter into agreement with third party with respect such right such term epizyme determine sole discretion style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center financial term style margin margin bottom text indent font size font family time roman execution payment within business after restatement date epizyme shall eisai refundable creditable payment forty million dollar style margin margin bottom text indent font size font family time roman development cost from after restatement date except otherwise expressly forth herein each party shall solely responsible development cost incurred such party affiliate internal cost such party affiliate performing activity connection with development licensed compound licensed product hereunder style margin margin bottom text indent font size font family time roman development milestone style margin margin bottom text indent font size font family time roman partial consideration amendment restatement prior agreement right license granted epizyme hereunder epizyme shall make creditable milestone payment eisai that forth below accordance with section nbsp upon first occurrence milestone event forth below style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman milestone event valign bottom nbsp nbsp valign bottom colspan align center style border bottom solid milestone payment valign bottom nbsp bgcolor cceeff style font family time roman font size valign style margin left text indent font size font family time roman earlier occur initiation behalf epizyme affiliate sublicensees first phase clinical trial licensed product indication specific patient population first submission behalf epizyme affiliate sublicensees united state major country through centralized approval procedure licensed product indication specific patient population valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman milestone event valign bottom nbsp nbsp valign bottom colspan align center style border bottom solid milestone payment valign bottom nbsp style font size height height colspan bgcolor cceeff style font family time roman font size valign style margin left text indent font size font family time roman earlier occur initiation behalf epizyme affiliate sublicensees first phase clinical trial licensed product either indication different from indication which previous phase clinical trial licensed product been initiated licensed product previously been submitted united state major country through centralized approval procedure same indication which previous phase clinical trial licensed product been initiated which licensed product previously been submitted united state major country through centralized approval procedure different specific patient population from specific patient population which previous phase clinical trial licensed product such indication been initiated which licensed product previously been submitted united state major country through centralized approval procedure first submission behalf epizyme affiliate sublicensees united state major country through centralized approval procedure licensed product either indication different from indication which previous phase clinical trial licensed product been initiated which licensed product previously been submitted united state major country through centralized approval procedure same indication which previous phase clinical trial licensed product been initiated which licensed product previously been submitted united state major country through centralized approval procedure different specific patient population from specific patient population which previous phase clinical trial licensed product such indication been initiated which licensed product previously been submitted united state major country through centralized approval procedure valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan style font family time roman font size valign style margin left text indent font size font family time roman first regulatory approval licensed product united state major country through centralized approval procedure indication specific patient population valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman milestone event valign bottom nbsp nbsp valign bottom colspan align center style border bottom solid milestone payment valign bottom nbsp style font size height height colspan bgcolor cceeff style font family time roman font size valign style margin left text indent font size font family time roman first regulatory approval licensed product united state major country through centralized approval procedure indication different from indication which previous regulatory approval licensed product been obtained same indication which previous regulatory approval licensed product been obtained different specific patient population from specific patient population which previous regulatory approval licensed product been obtained valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp table style margin margin bottom font size font family time roman milestone payment this section nbsp will made more than once irrespective number licensed product that have achieved milestone event forth this section nbsp maximum aggregate amount payable epizyme pursuant this section nbsp style margin margin bottom text indent font size font family time roman upon achievement behalf epizyme affiliate sublicensees milestone event listed above epizyme shall promptly event more than business after achievement thereof notify eisai such achievement epizyme shall eisai corresponding milestone payment within thirty after receipt invoice milestone payment from eisai which invoice shall sent eisai prior achievement such milestone event style margin margin bottom text indent font size font family time roman licensed product royalty style margin margin bottom text indent font size font family time roman royalty style margin margin bottom text indent font size font family time roman eisai territory royalty partial consideration amendment restatement prior agreement right license granted eisai hereunder subject section eisai shall epizyme royalty sale each therapeutic product eisai territory during royalty term such therapeutic product therapeutic product therapeutic product basis style margin margin bottom text indent font size font family time roman epizyme territory royalty partial consideration amendment restatement prior agreement right license granted epizyme hereunder subject section epizyme shall eisai royalty sale each therapeutic product each country epizyme territory during royalty term such therapeutic product such country therapeutic product therapeutic product basis style margin margin bottom text indent font size font family time roman royalty term adjustment style margin margin bottom text indent font size font family time roman each party royalty obligation under section nbsp shall commence country country licensed product licensed product basis date first commercial sale such party affiliate sublicensees relevant licensed product relevant country shall expire country country basis licensed product licensed product basis upon latest following royalty term applicable style margin margin bottom text indent font size font family time roman expiration patent based exclusivity with respect such licensed product such country style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman expiration regulatory based exclusivity with respect such licensed product such country style margin margin bottom text indent font size font family time roman tenth nbsp anniversary first commercial sale such licensed product such country such party affiliate sublicensees style margin margin bottom text indent font size font family time roman foregoing provision this section nbsp notwithstanding royalty payable with respect sale licensed product shall reduced licensed product licensed product country country basis percent amount otherwise payable pursuant section nbsp during portion royalty term when neither patent based exclusivity regulatory based exclusivity applies such licensed product such country style margin margin bottom text indent font size font family time roman each party shall have obligation royalty with respect sale licensed product country after royalty term such licensed product such country expired style margin margin bottom text indent font size font family time roman royalty reduction comparable third party product competition licensed product licensed product country country calendar quarter calendar quarter basis nbsp comparable third party product competition present with respect such licensed product such country during such calendar quarter nbsp court governmental agency competent jurisdiction requires applicable commercialization party affiliate sublicensees grant compulsory license third party permitting such third party make sell such licensed product such country such licensed product when sold such third party compulsory third party product such compulsory third party product have market share percent more aggregate market such country applicable licensed product compulsory third party product collectively based sale unit such licensed product such compulsory third party product reported international such data available such other reliable data source reasonably determined epizyme eisai used herein unit product mean equivalent amount product used equivalent treatment cycle such product then each case clause nbsp royalty payable with respect sale such licensed product pursuant section such country during such calendar quarter shall reduced percent royalty otherwise payable pursuant section style margin margin bottom text indent font size font family time roman third party payment style margin margin bottom text indent font size font family time roman subject section nbsp applicable commercialization party shall entitled credit against royalty other party sale licensed product country amount equal percent upfront payment milestone payment royalty other amount paid applicable commercialization party affiliate sublicensees third party with respect license right third party intellectual property licensed applicable commercialization party affiliate sublicensees from style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman applicable third party that applicable commercialization party reasonably belief necessary development manufacture commercialization such licensed product such country provided however that extent that such third party license includes license third party intellectual property that applicable product being developed commercialized applicable commercialization party affiliate other than such licensed product such country then applicable commercialization party shall reasonably allocate upfront payment milestone payment other royalty amount between licensed product such other product applicable commercialization party shall only entitled credit against royalty other party hereunder sale such licensed product percent amount that reasonably allocable licensed product addition applicable commercialization party shall entitled credit against royalty other party hereunder defense cost accordance with section nbsp style margin margin bottom text indent font size font family time roman event party enters into third party intellectual property license necessary development manufacture commercialization licensed product country other party part territory after restatement date epizyme represents warrant eisai that epizyme party such relevant third party license restatement date under which such party entitled grant sublicense other party other party will have right obtain such sublicense from such sublicensor party provided that such other party elect obtain such sublicense such other party shall percent amount payable third party account such sublicense either directly third party licensor sublicensor party party shall reasonably agree with goal ensuring timely payment third party such other party shall entitled credit against royalty sublicensor party sale such licensed product such country amount equal percent amount paid such other party either directly indirectly through sublicensor party such third party with respect such license right such licensed product such country style margin margin bottom text indent font size font family time roman amount becomes payable under license agreement under other agreement entered into epizyme affiliate with respect intellectual property that subject license agreement with respect development manufacture commercialization licensed product country world epizyme shall solely responsible shall such amount such amount shall creditable against royalty payable eisai hereunder style margin margin bottom text indent font size font family time roman aggregate limitation deduction notwithstanding anything contrary herein under circumstance shall combined effect reduction royalty payable party under section country country licensed product licensed product basis reduce effective royalty payable party pursuant this agreement calendar quarter below percent otherwise applicable royalty pursuant section nbsp provided that each party shall have right carry forward application against royalty payable other party with respect sale such licensed product such country future period amount that credited limitation this section nbsp style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman blended royalty each party acknowledges that nbsp licensed know know included regulatory material controlled other party proprietary valuable that without such know regulatory material such party would able obtain maintain regulatory approval with respect licensed product such party part territory nbsp such regulatory approval allow such party obtain maintain regulatory based exclusivity with respect licensed product nbsp access other party know right with respect regulatory material have provided such party with competitive advantage marketplace nbsp milestone payment royalty forth section respectively part intended compensate other party such exclusivity such competitive advantage party agree that royalty rate forth section reflect efficient reasonable blended allocation value provided such party other party style margin margin bottom text indent font size font family time roman report royalty payment style margin margin bottom text indent font size font family time roman until expiration each party royalty payment obligation under this article such party shall make written report other party within forty five after each calendar quarter covering sale licensed product font style white space nowrap font style white space nowrap product product font font country country basis applicable part territory such party affiliate sublicensees during such calendar quarter information contained each report under this section nbsp shall considered confidential information reporting party style margin margin bottom text indent font size font family time roman each such written report shall provide sale country licensed product period question adjustment made pursuant section addition foregoing each such written report shall with respect each major market country extent such information available with respect other country provide style margin margin bottom text indent font size font family time roman number unit sold each licensed product applicable style margin margin bottom text indent font size font family time roman gross sale each licensed product applicable style margin margin bottom text indent font size font family time roman calculation adjustment sale combination product applicable style margin margin bottom text indent font size font family time roman calculation royalty payment such sale pursuant this article style margin margin bottom text indent font size font family time roman concurrently with delivery each such report reporting party shall make royalty payment other party under this article calendar quarter covered such report style margin margin bottom text indent font size font family time roman method payment payment from party payor other party payee under this agreement shall paid dollar electronic fund transfer bank account designated writing payee style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman accounting style margin margin bottom text indent font size font family time roman each party agrees keep require affiliate sublicensees keep full clear accurate record minimum period three year after relevant payment owed pursuant this agreement setting forth sale other disposition licensed product sold otherwise disposed extent epizyme acting supplier eisai contemplated under section cost good sufficient detail enable royalty other amount payable other party under this agreement determined style margin margin bottom text indent font size font family time roman each party audited party further agrees upon than thirty prior written notice permit require affiliate sublicensees permit book record relating sale licensed product applicable cost good examined independent accounting firm selected other party auditing party reasonably acceptable audited party purpose verifying report provided audited party under section nbsp applicable cost good such audit shall nbsp performed more frequently than once twelve month period unless previous audit during such twelve month period revealed material discrepancy with respect such period nbsp conducted calendar quarter more than three year after calendar year which such calendar quarter part nbsp repeated calendar quarter shall conducted under appropriate confidentiality provision sole purpose verifying accuracy completeness report provided under section nbsp applicable cost good independent accounting firm shall have right make copy relevant portion audited party book record provided that such copy shall confidential information audited party shall protected appropriate confidentiality obligation shall shared with auditing party other person independent accounting firm will prepare provide eisai epizyme written report stating only whether report submitted amount paid hereunder were correct incorrect amount discrepancy style margin margin bottom text indent font size font family time roman such examination made expense auditing party except result audit reveal underpayment royalty auditing party audited party percent more calendar year overpayment eisai epizyme licensed compound licensed product supplied epizyme pursuant section nbsp percent more calendar year which case reasonable audit such examination shall paid audited party style margin margin bottom text indent font size font family time roman when calculating sale amount such sale foreign currency shall converted into dollar using standard methodology employed audited party consolidation purpose audited party shall provide reasonable documentation calculation reconciliation conversion figure product product country country basis part report sale period covered under applicable report style margin margin bottom text indent font size font family time roman epizyme shall keep shall require affiliate keep full clear accurate record development cost incurred epizyme affiliate performing activity connection with development licensed compound licensed product hereunder which record shall subject audit extent forth section nbsp style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman withholding payor shall inform payee withholding obligation imposed taxing authority payment payee under this agreement soon becomes aware withholding obligation nbsp party shall meet promptly thereafter discus best minimize amount such withholding obligation payee shall take reasonable lawful step requested payor minimize amount such withholding obligation payor expense nbsp party agree cooperate good faith provide another with such document certification reasonably necessary enable eisai epizyme minimize recover withholding payment nbsp eisai withhold event that revenue authority country outside united state require withholding amount paid hereunder epizyme epizyme withhold event that revenue authority country outside japan require withholding amount paid hereunder eisai such event payor shall deduct such from such payment such shall paid payor proper taxing authority behalf payee evidence which payment such taxing authority shall provided promptly payor payee hereunder notwithstanding foregoing provision this section nbsp eisai required taxing authority outside united state withhold from amount payable eisai hereunder epizyme required taxing authority outside japan withhold from amount payable epizyme hereunder then payor shall payee additional amount necessary that payee shall receive after deduction such withholding amount which payee would have received absence such withholding provided that such payment additional amount shall required extent required withholding result from payee assignment this agreement redomiciliation payee outside japan case eisai outside united state case epizyme style margin margin bottom text indent font size font family time roman late payment undisputed amount owed payor payee under this agreement that paid before date such payment shall bear interest rate annum equal lesser nbsp prime equivalent rate annum quoted wall street journal eastern edition first business after such payment plus basis point nbsp highest rate permitted applicable either case calculated number such payment paid after such payment compounded monthly interest shall accrue undisputed amount that were paid after date result mistaken payee action payment late result payee providing incorrect account receipt payment style margin margin bottom text indent font size font family time roman limitation payment notwithstanding anything herein contrary except otherwise forth last sentence this section nbsp royalty section nbsp shall apply provided that neither party sell unless until party have mutually agreed upon royalty payable sale such applicable accordance with this section nbsp party elect sole discretion written notice other party sell such applicable subject payment royalty forth section nbsp with respect such applicable event that party develops party shall negotiate downward adjustment royalty forth section nbsp sale such that reflects commercial potential such product standard commercial term industry applicable being understood that either party elect sole discretion upon written notice other party sell such applicable subject payment royalty forth section nbsp with respect such applicable style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman priority review voucher style margin margin bottom text indent font size font family time roman epizyme affiliate sublicensee awarded connection with licensed product epizyme such affiliate sublicensee thereafter sell such third party epizyme shall eisai percent total consideration that epizyme such affiliate sublicensee receives such sale within business after receipt such consideration epizyme shall notify eisai execution epizyme affiliate sublicensee agreement sale such third party shall provide eisai complete copy such sale agreement within nbsp business after such execution case such consideration received epizyme such affiliate sublicensee cash consideration value such cash consideration shall determined good faith party style margin margin bottom text indent font size font family time roman epizyme affiliate sublicensee awarded connection with licensed product epizyme such affiliate sublicensee thereafter redeems such with product other than licensed product then nbsp later than business after date such redemption redemption date epizyme shall notify eisai such redemption nbsp later than after redemption date eisai amount equal percent mean sale price prvs most recently sold third party prior redemption date avoidance doubt compensation shall payable epizyme eisai under this section nbsp epizyme affiliate sublicensee redeems with licensed product style margin margin bottom text indent font size font family time roman party unable reach agreement valuation pursuant section nbsp party will refer such matter jointly selected third party with expertise pricing pharmaceutical product that employee consultant legal advisor officer director stockholder have conflict interest with respect either party resolution party unable agree such third party expert within thirty after party notified other party that desire refer such matter such third party resolution either party request that york york office appoint such expert resolve such matter resolution determined such expert that either jointly selected appointed shall final binding party style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center exclusivity change control style margin margin bottom text indent font size font family time roman target exclusivity except licensed compound licensed product pursuant this agreement until expiration target exclusivity period neither party respective affiliate shall except otherwise permitted section nbsp either nbsp alone with third party develop manufacture development commercialization commercialize field compound directed anywhere territory nbsp grant license sublicense sell transfer asset including intellectual property otherwise assist contract with third party develop manufacture development commercialization commercialize field compound directed anywhere territory style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman exception notwithstanding foregoing style margin margin bottom text indent font size font family time roman change control event occurs with respect epizyme person that acquires combine with come control epizyme acquires epizyme asset result such change control event such person font style white space nowrap then existing font affiliate already program business that existed prior change control event that would otherwise violate section nbsp above time such change control event such program business extent that conduct thereof would otherwise violate section nbsp competing business such person such person affiliate shall permitted continue such competing business after such change control event such continuation shall constitute violation section nbsp above provided that style margin margin bottom text indent font size font family time roman development activity epizyme under this agreement shall conducted separately including separate personnel from development activity epizyme directed such competing business including maintenance separate notebook record style margin margin bottom text indent font size font family time roman epizyme shall continue comply with obligation hereunder including obligation under section nbsp style margin margin bottom text indent font size font family time roman either party affiliate merges consolidates transaction that constitute change control event with acquires third party with competing business either party affiliate acquires asset that include competing business case pursuant transaction series transaction which acquisition competing business ancillary principal focus transaction series transaction then such continuing operation competing business month following closing such transaction first series transaction shall constitute breach section nbsp party within month after closing date such transaction first series transaction either divests cause relevant affiliate divest competing business permanently cease cause relevant affiliate permanently cease operation competing business provided that event shall either party affiliate permitted merge consolidate with acquire third party that competing business acquire asset that include competing business pursuant transaction series transaction which acquisition competing business principal focus transaction series transaction style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center intellectual property right style margin margin bottom text indent font size font family time roman ownership style margin margin bottom text indent font size font family time roman intellectual property arising outside this agreement between party epizyme shall retain right title interest under epizyme eisai shall retain right title interest under eisai except extent that such right expressly licensed party other party under this agreement style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman intellectual property arising under this agreement style margin margin bottom text indent font size font family time roman eisai shall sole owner eisai collaboration know eisai collaboration patent eisai shall retain right title interest thereto except extent that right license expressly granted thereunder eisai epizyme under this agreement style margin margin bottom text indent font size font family time roman epizyme shall sole owner epizyme collaboration know epizyme collaboration patent epizyme shall retain right title interest thereto except extent that right license expressly granted thereunder epizyme eisai under this agreement style margin margin bottom text indent font size font family time roman joint patent joint font style white space nowrap know font shall owned jointly eisai epizyme right title interest thereto shall jointly owned party subject right license that expressly granted party other party under this agreement except extent either party restricted license granted party other party pursuant this agreement covenant contained herein each party shall entitled practice license joint know joint patent without restriction without consent subject financial provision this agreement obligation account other party each party hereby waif right have under require such consent accounting style margin margin bottom text indent font size font family time roman prosecution maintenance patent style margin margin bottom text indent font size font family time roman epizyme patent collaboration patent joint patent subject section nbsp style margin margin bottom text indent font size font family time roman between party epizyme shall have right obligation prosecute maintain epizyme patent collaboration patent joint patent epizyme shall keep eisai informed material development with respect prosecution maintenance such patent including providing copy substantive office action other substantive document that epizyme receives from patent office including notice interference reissue examination opposition request patent term extension style margin margin bottom text indent font size font family time roman epizyme shall also provide eisai with reasonable opportunity substantively comment prosecution maintenance epizyme patent collaboration patent joint patent prior taking material action including filing initial application will good faith consider action recommended eisai eisai shall have right review make comment recommendation relation prosecution maintenance such patent provided that eisai promptly consistent with applicable filing deadline style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman filing decision prosecution lapse during term party with first right pursuant section nbsp prosecute maintain epizyme patent collaboration patent joint patent applicable country decides file such patent intends allow such patent lapse become abandoned without having first filed substitute prosecuting maintaining party shall notify consult with other party such decision intention least prior date upon which subject matter such patent shall become unpatentable such patent shall lapse become abandoned such other party shall thereupon have right obligation assume prosecution maintenance thereof expense with counsel choice style margin margin bottom text indent font size font family time roman cooperation regarding filing prosecution patent style margin margin bottom text indent font size font family time roman party agree cooperate fully preparation filing prosecution maintenance epizyme patent that primarily applicable compound collaboration patent joint patent territory under this agreement cooperation shall include style margin margin bottom text indent font size font family time roman executing paper instrument requiring employee contractor execute such paper instrument nbsp effectuate ownership intellectual property forth section nbsp nbsp enable other party apply prosecute patent application territory nbsp obtain maintain patent extension supplementary protection certificate like with respect epizyme patent that primarily applicable compound collaboration patent joint patent each nbsp extent provided this agreement style margin margin bottom text indent font size font family time roman consistent with this agreement assisting license registration process with applicable governmental authority that available territory protection party interest this agreement style margin margin bottom text indent font size font family time roman promptly informing other party matter coming such party attention that materially affect preparation filing prosecution maintenance epizyme patent that primarily applicable compound collaboration patent joint patent territory style margin margin bottom text indent font size font family time roman either party request party shall cooperate with another file prosecute divisional patent application with respect epizyme patent that primarily applicable compound collaboration patent joint patent which either party responsible prosecution maintenance pursuant this section nbsp practicable necessary desirable divide subject matter relating development manufacture commercialization licensed compound licensed product from other subject matter style margin margin bottom text indent font size font family time roman united state determination whether know discovered developed invented conceived reduced practice made party purpose allocating proprietary right including patent other intellectual property right therein shall purpose this agreement made accordance with united state effect prior agreement effective date style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman create notwithstanding anything contrary this article neither party shall have right make election under cooperative research technology enhancement create when exercising right under this article without prior written consent other party with respect such permitted election party shall reasonable effort cooperate coordinate their activity with respect submission filing other activity support thereof party acknowledge agree that this agreement joint research agreement defined create style margin margin bottom text indent font size font family time roman patent cost each party shall responsible cost expense associated with prosecution maintenance activity under section nbsp provided that eisai will reimburse epizyme eisai territory specific pocket cost expense reasonably incurred epizyme prosecution maintenance epizyme patent collaboration patent joint patent eisai territory pursuant section nbsp within after receipt invoice from epizyme therefor style margin margin bottom text indent font size font family time roman defense claim brought third party party becomes aware claim suit proceeding alleging that development manufacture commercialization licensed compound licensed product infringes intellectual property right third party such party shall promptly notify other party subject article each party shall have first right obligation defend control defense such claim suit proceeding brought against such party expense subject deduction provided below using counsel choice other party participate such claim suit proceeding with counsel choice expense each party shall keep other party reasonably informed material development connection with such claim suit proceeding each party agrees provide other party with copy pleading filed such action allow other party reasonable opportunity participate defense claim each party shall entitled credit percent reasonable pocket cost defending such claim suit proceeding against royalty other party pursuant section nbsp recovery party sanction awarded such party against third party asserting claim being defended under this section nbsp shall applied follows such recovery shall applied first nbsp reimburse such party reasonable pocket cost defending such claim suit proceeding extent credited against royalty pursuant previous sentence nbsp reimburse other party royalty credit pursuant previous sentence extent amount recovery sufficient reimburse party total amount described under subsection nbsp nbsp above recovery shall shared party equally balance such recovery shall retained party defending such claim suit proceeding included such party sale relevant licensed product style margin margin bottom text indent font size font family time roman enforcement epizyme patent collaboration patent joint patent style margin margin bottom text indent font size font family time roman duty notify infringement party learns infringement threatened infringement third party with respect epizyme patent collaboration patent joint patent including actual alleged infringement under that would competitive with licensed compound licensed product competitive infringement such party shall promptly notify other party shall provide such other party with available evidence such competitive infringement style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman enforcement epizyme patent between party epizyme shall have primary right obligation institute prosecute control settle action proceeding with respect competitive infringement epizyme patent territory counsel choice eisai shall have right expense represented such action counsel choice epizyme fails bring action proceeding otherwise take affirmative action address such infringement within period after first being notified such competitive infringement after being notified case action brought under hatch waxman equivalent hatch waxman between party eisai shall have right bring control such action counsel choice epizyme shall have right represented such action counsel choice expense style margin margin bottom text indent font size font family time roman enforcement collaboration patent joint patent that cover licensed compound epizyme shall have primary right obligation institute prosecute control settle action proceeding with respect competitive infringement collaboration patent joint patent territory counsel choice eisai shall have right expense represented such action counsel choice epizyme fails bring action proceeding otherwise take affirmative action address such infringement within period after first being notified such competitive infringement after being notified case action brought under hatch waxman equivalent hatch waxman eisai shall have right bring control such action counsel choice epizyme shall have right represented such action counsel choice expense style margin margin bottom text indent font size font family time roman settlement settlement consent judgment other voluntary final disposition suit under this section nbsp entered into without consent party bringing suit provided that nbsp such settlement consent judgment other disposition action proceeding party under this article shall without consent party bringing suit impose liability obligation such party bringing suit nbsp party bringing suit shall settle enter into consent judgment dispose such claim suit proceeding except manner that belief good faith best interest licensed product without taking into consideration product such party portfolio that licensed product nbsp such settlement consent judgment other disposition action proceeding party under this article shall without consent party bringing suit conflict with reduce scope subject matter claimed patent owned solely jointly party bringing suit nbsp without prior written consent party bringing suit party bringing suit shall entitled grant license other party part territory that would conflict with license granted party bringing suit section nbsp section nbsp applicable style margin margin bottom text indent font size font family time roman cooperation party brings such action proceeding accordance with this section nbsp other party agrees joined party plaintiff where legally required initiate maintain suit collect damage give first party reasonable assistance authority file prosecute suit style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman cost recovery cost expense party bringing suit under this section nbsp shall borne such party damage other monetary award recovered shall shared follows style margin margin bottom text indent font size font family time roman amount such recovery actually received party controlling such action shall first applied pocket cost incurred each party connection with such action style margin margin bottom text indent font size font family time roman then remaining proceeds shall allocated between party such that party bringing suit under this section nbsp retains other party retains such amount style margin margin bottom text indent font size font family time roman regulatory data protection extent required epizyme shall commercially reasonable effort promptly accurately completely list with applicable regulatory authority during term applicable patent licensed product that epizyme intends begun commercialize that have become subject application regulatory approval submitted such listing include called orange book listing required under hatch waxman called patent register listing required canada prior such listing party shall meet evaluate identify applicable patent notwithstanding preceding sentence epizyme shall retain final decision making authority listing applicable patent such licensed product regardless which party owns such patent style margin margin bottom text indent font size font family time roman patent term extension epizyme eisai shall discus seek reach mutual agreement which patent within epizyme patent collaboration patent joint patent party shall apply obtain patent term extension adjustment restoration supplementary protection certificate under based best commercial interest licensed product covered such patent party unable reach mutual agreement between party epizyme shall have right make final decision such patent epizyme territory eisai shall have right make final decision such patent eisai territory style margin margin bottom text indent font size font family time roman invalidity unenforceability defense action style margin margin bottom text indent font size font family time roman notice third party asserts defense counterclaim infringement action under section nbsp claim counterclaim asserted under section nbsp declaratory judgment action similar action claim filed such third party either case that epizyme patent collaboration patent joint patent invalid unenforceable then party pursuing such infringement action party first obtaining knowledge such assertion shall promptly give written notice other party style margin margin bottom text indent font size font family time roman defense right defend applicable epizyme patent collaboration patent joint patent against such assertion invalidity unenforceability shall determined same manner right enforce such patent pursuant section nbsp style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman provided that assertion made suit that already being controlled party pursuant section nbsp controlling party shall retain control such defense other party participate such claim suit proceeding with counsel choice expense party elect defend control defense epizyme patent collaboration patent joint patent otherwise fails initiate maintain defense such claim suit proceeding then other party conduct control defense such claim suit proceeding expense style margin margin bottom text indent font size font family time roman cooperation each party shall assist cooperate with other party such other party reasonably request from time time connection with activity forth this section nbsp including being joined party plaintiff such action proceeding providing access relevant document other evidence making employee available reasonable business hour connection with such defense claim counterclaim controlling party shall consider good faith comment from other party shall keep other party reasonably informed step taken shall provide copy document filed connection with such defense claim counterclaim connection with activity forth this section nbsp each party shall consult with other strategy defense epizyme patent collaboration patent joint patent style margin margin bottom text indent font size font family time roman third party license reasonable opinion applicable commercialization party development manufacture commercialization licensed compound licensed product applicable commercialization party affiliate their sublicensees infringes misappropriates patent trade secret other intellectual property right third party country such party part territory such that applicable commercialization party affiliate their sublicensees develop manufacture commercialize such licensed compound licensed product such country without infringing such patent trade secret other intellectual property right such third party then applicable commercialization party shall have right obligation negotiate obtain license from such third party necessary applicable commercialization party affiliate their sublicensees develop manufacture commercialize licensed compound licensed product such country style margin margin bottom text indent font size font family time roman ownership prosecution product trademark applicable commercialization party shall right title interest trademark used with respect licensed product such party part territory shall responsible registration prosecution maintenance enforcement thereof clarity eisai same trademark eisai territory with respect licensed product epizyme epizyme territory with respect licensed product eisai shall such trademark eisai territory provided that nbsp eisai shall such trademark with respect product service other than licensed product nbsp upon effectiveness license granted epizyme under section nbsp applicable eisai agrees assign hereby assign epizyme right title interest such trademark eisai territory style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center confidentiality style margin margin bottom text indent font size font family time roman confidentiality exception except extent expressly authorized this agreement otherwise agreed writing party agree that receiving party receiving party shall keep confidential shall publish otherwise disclose purpose other than provided this agreement know other information material patentable otherwise form written oral photographic electronic magnetic otherwise which disclosed other party disclosing party otherwise received accessed receiving party course performing obligation exercising right under this agreement including trade secret know invention discovery proprietary information formula process technique information relating party past present future marketing financial development activity product potential product useful technology disclosing party pricing thereof collectively confidential information except extent that established receiving party that such confidential information style margin margin bottom text indent font size font family time roman lawful knowledge possession receiving party prior time disclosed learned receiving party otherwise developed independently receiving party evidenced written record kept ordinary course business other documentary proof actual receiving party style margin margin bottom text indent font size font family time roman generally available public otherwise part public domain time disclosure receiving party style margin margin bottom text indent font size font family time roman became generally available public otherwise part public domain after disclosure other than through omission receiving party breach this agreement style margin margin bottom text indent font size font family time roman disclosed receiving party other than under obligation confidentiality third party obligation disclosing party disclose such information others style margin margin bottom text indent font size font family time roman product information epizyme recognizes that reason inter alia eisai status exclusive licensee eisai territory under this agreement eisai interest epizyme retention confidence certain information epizyme accordingly until royalty term eisai territory epizyme shall keep confidential publish otherwise disclose purpose other than fulfill epizyme obligation exercise epizyme right hereunder epizyme know controlled epizyme epizyme collaboration know each case that primarily applicable compound product information except extent nbsp product information public domain through fault epizyme nbsp such disclosure expressly permitted under section nbsp nbsp such disclosure otherwise expressly permitted term condition this agreement purpose section nbsp each party shall deemed both disclosing party receiving party with respect product information clarification disclosure epizyme eisai product information shall cause such product information cease subject style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman provision this section nbsp with respect disclosure such confidential information epizyme event this agreement terminated pursuant article this section nbsp shall have continuing force effect product information extent disclosed epizyme eisai hereunder shall continue confidential information epizyme subject term section purpose surviving provision this agreement each party shall responsible compliance affiliate affiliate respective officer director employee agent with provision section nbsp this section nbsp style margin margin bottom text indent font size font family time roman authorized disclosure except expressly provided otherwise this agreement receiving party disclose confidential information disclosing party follows style margin margin bottom text indent font size font family time roman under appropriate confidentiality provision similar those this agreement connection with performance obligation exercise right granted reserved this agreement including right develop commercialize licensed compound licensed product grant license sublicenses hereunder style margin margin bottom text indent font size font family time roman regulatory authority required connection with filing application request regulatory approval provided however that reasonable measure shall taken assure confidential treatment such information style margin margin bottom text indent font size font family time roman response valid order court competent jurisdiction other supra national federal national regional state provincial local governmental regulatory body competent jurisdiction advised receiving party legal counsel such disclosure otherwise required including reason filing with security regulator provided however that extent practicable receiving party shall first have given notice disclosing party given disclosing party reasonable opportunity quash such order obtain protective order confidential treatment requiring that confidential information document that subject such order held confidence such court agency disclosed used only purpose which order issued provided further that confidential information disclosed response such court governmental order shall limited that information which legally required disclosed response such court governmental order style margin margin bottom text indent font size font family time roman patent authority reasonably necessary useful purpose obtaining enforcing patent with respect which receiving party right responsibility conduct such activity hereunder provided however that reasonable measure shall taken assure confidential treatment such information extent such protection available style margin margin bottom text indent font size font family time roman communication with actual potential investor lender acquirors merger partner consultant advisor licensee sublicensees collaborator others need know basis each case under appropriate confidentiality provision substantially equivalent those this agreement style margin margin bottom text indent font size font family time roman extent mutually agreed writing party style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman press release disclosure agreement style margin margin bottom text indent font size font family time roman press release promptly after restatement date each party shall issue public announcement this amendment restatement prior agreement form attached hereto epizyme announcement exhibit eisai announcement exhibit thereafter party shall good faith effort agree joint press release with respect material development relating development commercialization licensed product provided that nbsp epizyme shall have right without having obtain eisai consent issue press release make other public announcement disclosure with respect licensed product term this agreement party agree joint press release with respect thereto within five business after epizyme notifies eisai epizyme desire issue such press release nbsp eisai shall have right without having obtain epizyme consent issue press release make other public announcement disclosure with respect receipt eisai payment achievement milestone pursuant section nbsp this agreement party agree joint press release with respect thereto within five business after eisai notifies epizyme eisai desire issue such press release style margin margin bottom text indent font size font family time roman disclosure agreement term style margin margin bottom text indent font size font family time roman except extent required security exchange listing requirement otherwise permitted accordance with section nbsp neither party shall make public announcement concerning this agreement subject matter hereof without prior written consent other which shall unreasonably withheld conditioned delayed style margin margin bottom text indent font size font family time roman notwithstanding foregoing extent information regarding this agreement already been publicly disclosed either party subsequently disclose same information public without consent other party extent such information remains accurate each party shall also permitted disclose term this agreement each case under appropriate confidentiality provision substantially equivalent those this agreement actual potential acquirors merger partner licensee sublicensees collaborator investor lender professional advisor style margin margin bottom text indent font size font family time roman each party shall give other party reasonable opportunity review those portion filing with united state security exchange commission stock exchange including nasdaq similar regulatory agency country other than describing term this agreement including filing this agreement prior submission such filing shall give consideration reasonable comment filing party relating such filing including provision this agreement which confidential treatment should sought style margin margin bottom text indent font size font family time roman termination prior confidentiality agreement this agreement supersedes replaces confidentiality agreement between epizyme eisai dated july nbsp existing confidentiality agreement information exchanged between party under existing confidentiality agreement shall deemed confidential information hereunder shall subject term this article style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman remedy each party shall entitled seek addition other right remedy have equity temporary injunction without posting bond other security enjoining restraining other party from violation threatened violation this article style margin margin bottom text indent font size font family time roman publication style margin margin bottom text indent font size font family time roman publication restriction neither eisai affiliate shall publish publicly disclose result generated course performing development commercialization activity directed conducted either party under this agreement without prior written consent epizyme except nbsp eisai publish publicly disclose result generated course performing japan specific development activity conducted eisai under this agreement without such consent subject eisai first providing epizyme with opportunity review proposed publication forth section nbsp nbsp otherwise expressly permitted section nbsp otherwise this agreement epizyme publish publicly disclose result generated course performing development commercialization activity directed conducted epizyme under this agreement without prior written consent eisai subject epizyme first providing eisai with opportunity review proposed publication forth section nbsp otherwise expressly permitted section nbsp otherwise this agreement style margin margin bottom text indent font size font family time roman submission review party seeking publish result hereunder publishing party shall provide other party reviewing party with copy such proposed abstract manuscript presentation than fifteen prior intended submission publication reviewing party shall respond writing promptly event later than after receipt proposed material with more following style margin margin bottom text indent font size font family time roman comment proposed material which publishing party shall consider good faith style margin margin bottom text indent font size font family time roman specific statement concern based upon need seek patent protection block publication reviewing party determines that proposed disclosure intellectual property that should maintained trade secret protect compound development activity conducted under this agreement style margin margin bottom text indent font size font family time roman identification reviewing party confidential information that contained material reviewed style margin margin bottom text indent font size font family time roman patent trade secret protection event concern reviewing party over patent protection whether maintaining trade secret would priority publishing party agrees submit such publication make such presentation that contains such information until reviewing party given reasonable period time event than seek patent protection material such publication presentation which belief patentable resolve other issue abandon such proposed publication presentation reviewing party reasonably determines good faith style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman that maintaining such information trade secret commercially reasonable priority confidential information reviewing party shall requested reviewing party removed style margin margin bottom text indent font size font family time roman review third party material with respect proposed abstract manuscript summary presentation investigator other third party conducting development with behalf party hereunder such material shall subject review other party under this section nbsp same extent that eisai epizyme case right style margin margin bottom text indent font size font family time roman clinical trial register each eisai epizyme shall have right list publish summary data result from human clinical trial conducted such party under this agreement clinical trial registry government sponsored database such clinicaltrials other publicly available website such clinicalstudyresults without requiring consent other party party shall discus reasonably cooperate order facilitate process employed order ensure publication such summary human clinical trial data result required clinical trial registry each party government sponsored database such clinicaltrials other publicly available website such clinicalstudyresults shall provide copy such summary other party least thirty prior proposed publication date purpose preparing necessary patent filing style margin margin bottom text indent font size font family time roman name except expressly provided herein neither party shall mention otherwise name logo trademark other party affiliate abbreviation adaptation thereof publication press release marketing promotional material other form publicity without prior written approval such other party each instance restriction imposed this section nbsp shall prohibit either party from making disclosure identifying other party that required addition epizyme eisai name logo trademark epizyme website identify eisai epizyme collaborator provided that epizyme complies with formatting specification provided eisai style margin margin bottom text indent font size font family time roman return confidential information upon effective date expiration termination this agreement reason either party request writing other party shall either with respect confidential information which such first party retain right under surviving provision this agreement nbsp promptly destroy copy such confidential information possession other party confirm such destruction writing requesting party nbsp promptly deliver requesting party other party expense copy such confidential information possession other party provided however that other party shall permitted retain such confidential information sole purpose performing continuing obligation hereunder exercising right hereunder that survive such termination exercise right under license grant back notwithstanding foregoing such other party also shall permitted retain nbsp copy such confidential information archival purpose such additional copy computer record file containing such confidential information that have been created solely such party automatic archiving back procedure extent created retained manner consistent with such other party standard archiving back procedure other purpose confidential information shall continue subject term this agreement period forth section nbsp style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center representation warranty style margin margin bottom text indent font size font family time roman representation warranty both party each party hereby represents warrant covenant other party restatement date that style margin margin bottom text indent font size font family time roman such party duly organized validly existing good standing under jurisdiction incorporation full corporate power authority enter into this agreement carry provision hereof style margin margin bottom text indent font size font family time roman such party taken necessary action part authorize execution delivery this agreement performance obligation hereunder style margin margin bottom text indent font size font family time roman this agreement been duly executed delivered behalf such party constitutes legal valid binding obligation enforceable against accordance with term hereof style margin margin bottom text indent font size font family time roman execution delivery performance this agreement such party will conflict with agreement provision thereof instrument understanding oral written which becomes party which becomes bound violate regulation court governmental body administrative other agency having jurisdiction over such party style margin margin bottom text indent font size font family time roman government authorization consent approval license exemption filing registration with court governmental department commission board bureau agency instrumentality domestic foreign under currently effect necessary execution delivery this agreement style margin margin bottom text indent font size font family time roman nbsp employed used contractor consultant that employed person debarred pursuant section nbsp federal food drug cosmetic ffdca subject conviction described such section subject similar sanction nbsp employed person that subject debarment investigation proceeding similar proceeding conduct clinical activity clinical study compound style margin margin bottom text indent font size font family time roman representation warranty epizyme epizyme hereby represents warrant covenant eisai restatement date that style margin margin bottom text indent font size font family time roman epizyme patent eisai territory existing restatement date listed exhibit such epizyme patent existing restatement date collectively existing patent epizyme knowledge issued patent included existing patent invalid unenforceable style margin margin bottom text indent font size font family time roman reserved style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman there claim judgment settlement against amount with respect thereto owed epizyme affiliate relating existing patent epizyme know existing restatement date such epizyme know existing restatement date collectively existing know claim litigation been brought threatened against epizyme affiliate person alleging epizyme knowledge claim whether asserted that nbsp existing patent invalid unenforceable nbsp existing patent existing know disclosing copying making assigning licensing existing patent existing know development commercialization licensed compound licensed product prior restatement date violated infringed otherwise conflicted interfered with intellectual property proprietary right person nbsp disclosing copying making assigning licensing existing patent existing know development commercialization licensed compound licensed product contemplated herein would violate infringe otherwise conflict interfere with intellectual property proprietary right person style margin margin bottom text indent font size font family time roman except existing patent existing know which eisai joint owner epizyme sole exclusive owner existing patent existing know free encumbrance lien claim ownership third party epizyme entitled grant eisai license specified herein style margin margin bottom text indent font size font family time roman during term epizyme shall encumber diminish right with respect epizyme patent each case such encumbrance diminution would adversely affect right license granted eisai obligation eisai epizyme hereunder without prior written consent eisai style margin margin bottom text indent font size font family time roman epizyme knowledge existing patent being diligently prosecuted respective patent office accordance with applicable filing maintenance with respect existing patent have been paid before date payment style margin margin bottom text indent font size font family time roman epizyme affiliate have previously assigned transferred licensed conveyed otherwise encumbered their right title interest existing patent that primarily applicable compound existing know that primarily applicable compound compound including granting covenant with respect thereto patent know that would existing patent existing know each case that primarily applicable compound such assignment transfer license conveyance encumbrance except each case where such assignment transfer license conveyance encumbrance terminated longer force effect epizyme affiliate will enter into such agreement grant such right title interest person that inconsistent with right license granted eisai under this agreement epizyme obligation under this agreement style margin margin bottom text indent font size font family time roman epizyme knowledge person infringing threatening infringe existing patent misappropriating threatening misappropriate existing know style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman true complete correct copy nbsp file wrapper other material document relating prosecution defense maintenance validity enforceability existing patent were provided made available eisai prior prior agreement date nbsp information known epizyme that epizyme belief materially adverse with respect safety efficacy compound controlled epizyme restatement date were provided made available eisai prior restatement date style margin margin bottom text indent font size font family time roman epizyme knowledge conduct development activity hereunder contemplated restatement date will infringe patent other intellectual property proprietary right person style margin margin bottom text indent font size font family time roman conception development reduction practice existing patent existing know have constituted involved misappropriation trade secret other right property person conception development reduction practice collaboration patent collaboration know each case behalf epizyme affiliate prior restatement date have constituted involved misappropriation trade secret other right property person style margin margin bottom text indent font size font family time roman respect pending patent application included existing patent epizyme complied with duty candor relevant patent office style margin margin bottom text indent font size font family time roman existing patent represent patent within epizyme control relating compound eisai territory restatement date epizyme knowledge there know controlled epizyme restatement date that relates compound that within existing know style margin margin bottom text indent font size font family time roman epizyme knowledge each existing patent properly identifies each every inventor claim thereof determined accordance with jurisdiction which such existing patent issued such application pending style margin margin bottom text indent font size font family time roman epizyme knowledge each person right existing patent existing know assigned executed agreement assigning entire right title interest such existing patent existing know epizyme style margin margin bottom text indent font size font family time roman material existing know owned epizyme have been disclosed authorized disclosed third party subject confidentiality obligation epizyme epizyme knowledge third party such nondisclosure agreement with epizyme breach default thereof epizyme implemented reasonable policy procedure protect maintain confidentiality existing know style margin margin bottom text indent font size font family time roman information documentation other material furnished made available epizyme upon request eisai during eisai period diligence prior prior agreement effective date were date such information documentation material were furnished made available eisai true complete correct copy what they purport style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman epizyme affiliate have conducted epizyme knowledge their respective contractor consultant have conducted development licensed compound licensed product that they have conducted prior restatement date accordance with style margin margin bottom text indent font size font family time roman representation warranty eisai eisai hereby represents warrant epizyme restatement date that nbsp eisai knowledge neither eisai affiliate owns control right compound except licensed compound which been granted right hereunder nbsp eisai entitled grant epizyme license specified herein nbsp conception development reduction practice collaboration patent collaboration know each case behalf eisai affiliate prior restatement date have constituted involved misappropriation trade secret other right property person style margin margin bottom text indent font size font family time roman mutual covenant each party hereby covenant other party that style margin margin bottom text indent font size font family time roman employee such party affiliate working under this agreement will under obligation assign right title interest their invention discovery whether patentable such party sole owner thereof style margin margin bottom text indent font size font family time roman shall capacity connection with performance activity contemplated this agreement person been debarred pursuant section nbsp ffdca subject conviction described such section subject similar sanction agrees inform other party writing immediately person performing service hereunder behalf debarred subject conviction described section nbsp action suit claim investigation legal administrative proceeding pending knowledge threatened relating debarment conviction person performing service hereunder style margin margin bottom text indent font size font family time roman neither party shall during term grant right license third party relating intellectual property right owns control which would conflict with right license granted other party hereunder such party obligation hereunder style margin margin bottom text indent font size font family time roman disclaimer except otherwise expressly forth this agreement neither party make representation extends warranty kind either express implied expressly disclaims implied warranty merchantability fitness particular purpose noninfringement without limiting generality foregoing each party disclaims warranty with regard nbsp success study test commenced under this agreement nbsp safety usefulness purpose technology material including compound provides discovers under this agreement style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center indemnification insurance style margin margin bottom text indent font size font family time roman indemnification eisai eisai shall indemnify defend hold harmless epizyme affiliate their respective director officer employee agent from against liability damage loss cost expense including reasonable attorney other professional third party collectively loss arising resulting from third party suit claim action proceeding demand third party claim based upon style margin margin bottom text indent font size font family time roman negligence recklessness wrongful intentional omission eisai affiliate their respective director officer employee agent connection with eisai performance obligation exercise right under this agreement style margin margin bottom text indent font size font family time roman breach representation warranty covenant made eisai under article other provision under this agreement style margin margin bottom text indent font size font family time roman development that actually conducted behalf eisai affiliate sublicensees excluding development carried behalf epizyme affiliate sublicensees hereunder handling storage behalf eisai affiliate sublicensees chemical agent other compound purpose conducting development behalf eisai affiliate sublicensees manufacture commercialization eisai affiliate sublicensees licensed compound licensed product including nbsp product liability personal injury property damage other damage resulting from licensed compound licensed product distributed behalf eisai affiliate sublicensees nbsp infringement patent other intellectual property right third party eisai affiliate sublicensees each case resulting from foregoing activity described this section nbsp style margin margin bottom text indent font size font family time roman development commercialization manufacture compound licensed compound licensed product anywhere world after term including marketing related material behalf eisai affiliate third party sublicensees style margin margin bottom font size font family time roman each case provided that such indemnity shall apply extent epizyme indemnification obligation pursuant section nbsp such loss which event each party shall indemnify other extent their respective liability such loss style margin margin bottom text indent font size font family time roman indemnification epizyme epizyme shall indemnify defend hold harmless eisai affiliate their respective director officer employee agent from against loss arising resulting from third party claim based upon style margin margin bottom text indent font size font family time roman negligence recklessness wrongful intentional omission epizyme affiliate their respective director officer employee agent connection with epizyme performance obligation exercise right under this agreement style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman breach representation warranty covenant made epizyme under article other provision under this agreement style margin margin bottom text indent font size font family time roman development that actually conducted behalf epizyme affiliate sublicensees including development carried eisai affiliate pursuant exhibit without expanding epizyme obligation cost activity conducted pursuant exhibit section nbsp beyond epizyme payment obligation forth section nbsp otherwise excluding development carried behalf eisai affiliate sublicensees provided however that development which carried behalf epizyme affiliate sublicensees hereunder shall considered interpreted development carried behalf eisai affiliate sublicensees handling storage behalf epizyme affiliate sublicensees chemical agent other compound purpose conducting development behalf epizyme affiliate sublicensees including handling storage eisai affiliate chemical agent other compound pursuant exhibit manufacture commercialization epizyme affiliate sublicensees licensed compound licensed product including nbsp product liability personal injury property damage other damage resulting from licensed compound licensed product distributed behalf epizyme affiliate sublicensees nbsp infringement patent other intellectual property right third party epizyme affiliate sublicensees each case resulting from foregoing activity described this section nbsp style margin margin bottom text indent font size font family time roman gross negligence recklessness wrongful intentional omission failure comply with breach agreement with third party infringement patent other intellectual property right third party epizyme affiliate third party sublicensees with respect development commercialization manufacture licensed compound licensed product anywhere world prior prior agreement effective date style margin margin bottom text indent font size font family time roman development commercialization manufacture compound licensed compound licensed product anywhere world after term including marketing related material behalf epizyme affiliate third party sublicensees style margin margin bottom text indent font size font family time roman development commercialization manufacture compound licensed compound licensed product eisai territory after termination this agreement with respect eisai territory including marketing related material behalf epizyme affiliate third party sublicensees style margin margin bottom font size font family time roman each case provided that such indemnity shall apply extent eisai indemnification obligation pursuant section nbsp such loss which event each party shall indemnify other extent their respective liability such loss style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman procedure style margin margin bottom text indent font size font family time roman notice claim person seeking indemnification under this article indemnified party shall give prompt written notification party from whom indemnification sought indemnifying party third party claim which indemnification sought being understood agreed however that failure indemnified party give notice third party claim provided this section nbsp shall relieve indemnifying party indemnification obligation under this agreement except only extent that such indemnifying party actually prejudiced result such failure give notice style margin margin bottom text indent font size font family time roman assumption defense participation within after delivery such notification indemnifying party upon written notice thereof indemnified party assume control defense such third party claim with counsel reasonably satisfactory indemnified party indemnifying party assume control such defense indemnified party shall control such defense without limiting indemnifying party indemnification obligation indemnifying party shall reimburse indemnified party cost expense including reasonable attorney disbursement incurred indemnified party defending itself within after receipt invoice therefor from indemnified party party controlling such defense participate therein expense provided however that indemnifying party assumes control such defense indemnified party good faith concludes based written advice from outside counsel that indemnifying party indemnified party have conflicting interest with respect such third party claim sufficiently adverse make unadvisable representation same counsel both party under ethical rule equitable principle indemnifying party shall responsible reasonable expense single counsel indemnified party connection therewith party controlling such defense shall keep other party advised status such third party claim defense thereof shall consider recommendation made other party with respect thereto style margin margin bottom text indent font size font family time roman settlement indemnified party shall agree settlement such third party claim without prior written consent indemnifying party which shall unreasonably withheld delayed conditioned indemnifying party shall agree settlement such third party claim consent judgment respect thereof that include complete unconditional release indemnified party from liability with respect thereto that imposes liability obligation indemnified party that acknowledges fault indemnified party without prior written consent indemnified party style margin margin bottom text indent font size font family time roman insurance style margin margin bottom text indent font size font family time roman epizyme insurance obligation epizyme shall maintain cost insurance against liability other risk associated with activity obligation under this agreement such amount subject such deductible such term customary company such epizyme activity conducted under this agreement epizyme shall furnish eisai evidence such insurance upon request style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman eisai insurance obligation eisai shall maintain self insurance against liability other risk associated with activity obligation under this agreement including clinical trial commercialization licensed product such amount such term customary company such eisai activity conducted under this agreement eisai shall furnish epizyme evidence such self insurance upon request style margin margin bottom text indent font size font family time roman limitation liability except breach article article claim third party that subject indemnification under this article neither epizyme eisai their respective affiliate sublicensees will liable other party this agreement affiliate their sublicensees indirect incidental consequential special punitive damage lost profit lost royalty other than royalty other party hereunder actual sale lost data cost procurement substitute good service whether liability asserted contract tort including negligence strict product liability indemnity contribution irrespective whether that party representative that party been advised otherwise might have anticipated possibility such loss damage style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center term termination style margin margin bottom text indent font size font family time roman term expiration style margin margin bottom text indent font size font family time roman term this agreement shall become effective prior agreement effective date unless earlier terminated pursuant this article shall remain effect until expiration payment obligation under this agreement with respect licensed product country territory term style margin margin bottom text indent font size font family time roman effect expiration royalty term after expiration applicable royalty term with respect licensed product country territory after earlier termination this agreement applicable commercialization party shall have exclusive fully paid royalty free right license with right grant sublicenses under know patent licensed such party hereunder each case used time such expiration continue develop commercialize such licensed product field such country long continues style margin margin bottom text indent font size font family time roman unilateral termination style margin margin bottom text indent font size font family time roman termination convenience style margin margin bottom text indent font size font family time roman epizyme shall have right sole discretion exercisable time terminate this agreement with respect epizyme territory upon ninety nbsp prior written notice eisai hereunder style margin margin bottom text indent font size font family time roman eisai shall have right sole discretion exercisable time terminate this agreement with respect eisai territory upon ninety nbsp prior written notice epizyme hereunder style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman cessation activity without limiting generality section nbsp party designated affiliate sublicensee material respect cease fails undertake development commercialization activity with respect licensed compound licensed product with respect epizyme united state united kingdom germany france spain italy with respect eisai japan excluding each case temporary cessation during period which such party using commercially reasonable effort prepare resume commence development commercialization temporary cessation during period month which such party conducting strategic review licensed product order determine whether resume commence development commercialization then such cessation failure consistent with exercise commercially reasonable effort therefore breach such party obligation commercially reasonable effort that basis termination other party pursuant section nbsp such cessation failure shall nonetheless deemed constitute termination party which cease fails undertake such development commercialization activity under section nbsp with respect eisai territory case eisai terminating party with respect epizyme territory case epizyme terminating party clarity cessation under this section nbsp with respect party part territory shall deemed have occurred nbsp such party designated affiliate sublicensee performing development commercialization activity with respect least nbsp licensed compound licensed product with respect such party part territory nbsp such party affiliate engaged active negotiation with third party connection with license sublicense such party part territory with respect licensed compound licensed product style margin margin bottom text indent font size font family time roman termination cause style margin margin bottom text indent font size font family time roman termination material breach style margin margin bottom text indent font size font family time roman either party breaching party without prejudice other remedy available under equity terminate this agreement other party breaching party shall have materially breached performance obligation hereunder such breach shall have continued case payment breach after written notice thereof provided breaching party breaching party such notice describing alleged breach subject section nbsp such termination this agreement under this section nbsp shall become effective such applicable cure period unless style margin margin bottom text indent font size font family time roman breaching party cured such breach prior expiration such cure period style margin margin bottom text indent font size font family time roman such breach susceptible cure within such cure period even with commercially reasonable effort which event breaching party right termination shall suspended only long nbsp breaching party style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman provided breaching party written plan that reasonably calculated effect cure nbsp such plan acceptable breaching party nbsp breaching party commits carry such plan provided that unless otherwise mutually agreed party event shall such suspension breaching party right terminate extend beyond after original cure period style margin margin bottom text indent font size font family time roman notwithstanding foregoing provision this section nbsp nbsp applicable material breach material breach eisai obligation under section nbsp then epizyme termination right pursuant this section nbsp with respect such breach shall limited termination only eisai territory nbsp applicable material breach material breach eisai obligation under section nbsp then epizyme elect limit such termination eisai territory style margin margin bottom text indent font size font family time roman notwithstanding foregoing provision this section nbsp applicable material breach material breach epizyme obligation under section nbsp then eisai termination right pursuant this section with respect such breach shall limited termination only epizyme territory nbsp applicable material breach material breach epizyme obligation under section nbsp then eisai elect limit such termination epizyme territory style margin margin bottom text indent font size font family time roman right either party terminate this agreement portion this agreement provided this section nbsp shall affected such party waiver failure take action with respect previous material breach style margin margin bottom text indent font size font family time roman disagreement party reasonably good faith disagree whether there been material breach party that seek dispute that there been material breach contest allegation accordance with section nbsp cure period allegation made good faith material breach under this agreement will subject section from date that written notice first provided breaching party breaching party style margin margin bottom text indent font size font family time roman termination eisai patent challenge eisai affiliate sublicensees style margin margin bottom text indent font size font family time roman commences otherwise voluntarily determines participate other than necessary reasonably required assert cross claim counter claim respond court request order administrative request order action proceeding including patent opposition examination proceeding challenging denying validity epizyme patent collaboration patent owned epizyme claim foregoing style margin margin bottom text indent font size font family time roman actively assist other person other than necessary reasonably required assert cross claim counter claim respond court request order administrative request order bringing prosecuting action proceeding including patent opposition examination proceeding challenging denying validity such patent claim thereof each activity under foregoing clause nbsp eisai patent challenge style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman then epizyme shall have right terminate this agreement upon thirty nbsp written notice eisai style margin margin bottom text indent font size font family time roman effect termination style margin margin bottom text indent font size font family time roman termination eisai convenience termination epizyme cause patent challenge nbsp this agreement terminated entirety result eisai uncured breach pursuant section nbsp nbsp epizyme terminates this agreement with respect eisai territory result eisai uncured breach pursuant section nbsp nbsp epizyme terminates this agreement entirety result eisai patent challenge pursuant section nbsp nbsp eisai terminates this agreement with respect eisai territory pursuant section nbsp including deemed termination pursuant section nbsp then style margin margin bottom text indent font size font family time roman effect license license granted eisai under this agreement shall terminated further force effect license granted epizyme under section nbsp this agreement shall survive remain full force effect provided that such license under section nbsp shall limited eisai collaboration joint each case controlled eisai effective date termination used effective date termination development manufacture commercialization licensed compound licensed product they exist date termination style margin margin bottom text indent font size font family time roman summary activity within after such termination eisai shall provide epizyme fair accurate summary report status result affiliate sublicensees development commercialization activity licensed compound licensed product prior effective date termination field eisai territory style margin margin bottom text indent font size font family time roman transition assistance without limiting generality remainder this section nbsp eisai shall commercially reasonable effort epizyme cost effect seamless timely transition epizyme development manufacturing commercialization activity responsibility licensed compound licensed product eisai territory they exist date termination accordance with transition plan mutually agreed party style margin margin bottom text indent font size font family time roman license grant epizyme effective upon such termination eisai hereby grant epizyme perpetual irrevocable royalty bearing royalty rate specified nbsp section nbsp such termination termination described foregoing clause nbsp this section nbsp nbsp section nbsp such termination termination described foregoing clause nbsp nbsp this section nbsp eisai territory were each case subject section mutatis mutandis exclusive right license even eisai affiliate with right grant sublicenses under eisai collaboration joint each case controlled eisai effective date termination used effective date termination development manufacture commercialization licensed compound licensed product they exist date termination solely continue develop manufacture commercialize such licensed compound licensed product field eisai territory provided that style margin margin bottom text indent font size font family time roman foregoing license shall exclude license other right with respect therapeutically active pharmaceutical ingredient that licensed compound which covered patent controlled eisai affiliate style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman eisai shall provide epizyme with copy third party agreement with respect eisai eisai collaboration that subject license granted eisai epizyme pursuant this section nbsp epizyme time thereafter exclude eisai eisai collaboration that subject such third party agreement from grant forth this section nbsp written notice eisai which event clause nbsp below shall apply thereafter such third party agreement epizyme shall have obligation with respect amount that become payable under such third party agreement style margin margin bottom text indent font size font family time roman epizyme shall responsible nbsp making payment including royalty milestone other amount payable eisai third party under such third party agreement that applicable grant epizyme such license exercise such license epizyme affiliate sublicensees making such payment directly eisai each instance epizyme shall make requisite payment eisai provide necessary reporting information eisai sufficient time enable eisai comply with obligation under such third party agreement nbsp complying with other obligation included such third party agreement that applicable grant epizyme such license exercise such license epizyme affiliate sublicensees style margin margin bottom text indent font size font family time roman eisai shall responsible paying providing such third party payment report made provided epizyme under this section nbsp style margin margin bottom text indent font size font family time roman clinical development activity with respect clinical development activity eisai territory that progress time notice termination nbsp epizyme elect sole discretion complete such clinical development activity which event eisai shall transfer epizyme designee such clinical development activity part transition plan mutually agreed party under clause nbsp above epizyme expense nbsp epizyme elect complete such clinical development activity eisai shall promptly discontinue wind down eisai cost such clinical development activity forward interim final report underlying data from such activity epizyme designee style margin margin bottom text indent font size font family time roman regulatory filing extent permitted eisai will promptly assign epizyme regulatory approval regulatory dossier regulatory material licensed product eisai territory eisai restricted under from transferring ownership foregoing item epizyme including order continue conduct transition activity contemplated this section nbsp including conduct clinical development activity applicable pursuant section nbsp above eisai shall grant style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman epizyme designee right reference such item being understood that eisai shall commercially reasonable effort transfer same epizyme after completion such transition activity eisai shall take action reasonably necessary effect such transfer grant right reference epizyme including making such filing required with regulatory authority other governmental authority territory that necessary record such assignment effect such transfer style margin margin bottom text indent font size font family time roman marketing related material upon epizyme request eisai will promptly transfer deliver epizyme designee promotional material used eisai effective date termination promotion licensed product eisai territory marketing related material effective such termination eisai hereby grant epizyme perpetual irrevocable fully paid exclusive license with right grant sublicenses reproduce distribute display modify exploit directly indirectly such marketing related material each case solely connection with exploitation licensed product provided that neither epizyme affiliate sublicensees shall have right license reproduce distribute display modify exploit corporate name logo eisai affiliate such material epizyme acknowledges agrees that nbsp eisai make representation warranty kind express implied with respect such material including warranty that material purpose that material will infringe intellectual property right person entity nbsp neither eisai affiliate shall have liability kind epizyme affiliate third party resulting from connection with such material person entity style margin margin bottom text indent font size font family time roman trademark first commercial sale licensed product eisai territory occurred effective date termination epizyme request cost eisai shall assign epizyme eisai trademark used with respect licensed product other than eisai company specific name company specific logo solely connection with such licensed product style margin margin bottom text indent font size font family time roman transfer data upon epizyme request eisai will promptly provide epizyme designee copy pharmacological toxicological clinical test data result research data report batch record safety data other data including related information formulation information chemistry biology data controlled eisai effective date termination used effective date termination development manufacture commercialization eisai territory licensed product they exist effective date termination which previously been provided epizyme style margin margin bottom text indent font size font family time roman contract eisai shall assign epizyme extent assignable included transition plan agreed party under clause nbsp above eisai right third party agreement license service supply used connection with development manufacture commercialization licensed product eisai territory including third party manufacturing agreement clinical trial agreement subject style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman clause nbsp above unless such agreement cover combination product which active pharmaceutical ingredient that licensed compound covered patent controlled eisai affiliate manufacturing agreement relating licensed product eisai shall commercially reasonable effort require that agreement assignable epizyme upon termination this agreement extent that such agreement assignable eisai then such agreement will assigned upon request epizyme eisai will cooperate good faith commercially reasonable effort allow epizyme obtain enjoy benefit such agreement form license other right extent held eisai subject such third party right addition extent that such third party agreement specific licensed product eisai need retain such agreement purpose unrelated applicable licensed product eisai will cooperate good faith commercially reasonable effort allow epizyme obtain enjoy benefit such agreement with respect applicable licensed product form sublicense subcontract other right subject such third party right style margin margin bottom text indent font size font family time roman manufacturing upon epizyme request eisai shall part transition plan mutually agreed party under clause nbsp above epizyme expense transfer epizyme designee process document material other know extent foregoing controlled eisai effective date termination used manufacture licensed product field they exist date termination style margin margin bottom text indent font size font family time roman existing inventory epizyme election eisai will transfer epizyme such portion eisai existing inventory licensed product including clinical trial material synthetic intermediate applicable that epizyme elect with respect commercial supply that good saleable condition original unopened packaging style margin margin bottom text indent font size font family time roman prosecution enforcement provision article shall terminated except section nbsp addition between party epizyme shall have right obligation prosecute maintain enforce eisai collaboration patent that primarily applicable compound licensed epizyme pursuant clause nbsp above under same term same extent epizyme right prosecute maintain enforce eisai collaboration patent under article during term eisai shall provide such assistance cooperation reasonably necessary connection with transition prosecution enforcement responsibility epizyme with respect such eisai collaboration patent including execution such document necessary effect such transition style margin margin bottom text indent font size font family time roman epizyme territory obligation remain clarity eisai terminates this agreement with respect eisai territory pursuant section nbsp including deemed termination pursuant section nbsp epizyme terminates this agreement with respect eisai territory pursuant section nbsp this agreement party right obligation with respect epizyme territory shall remain full force effect including epizyme obligation under article provided that solely epizyme terminates this agreement with respect eisai territory pursuant section nbsp style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman effective date such termination section nbsp shall terminated further force effect clarity epizyme shall obligated accordance with section nbsp milestone payment with respect milestone event under section nbsp achieved effective date termination paid epizyme effective date termination style margin margin bottom text indent font size font family time roman payment obligation payment obligation that have accrued that have been satisfied prior date such termination shall survive style margin margin bottom text indent font size font family time roman termination eisai cause termination epizyme convenience nbsp eisai terminates this agreement with respect epizyme territory pursuant section nbsp result epizyme uncured breach nbsp eisai terminates this agreement entirety pursuant section nbsp result epizyme uncured material breach nbsp epizyme terminates this agreement with respect epizyme territory pursuant section nbsp including deemed termination pursuant section nbsp then style margin margin bottom text indent font size font family time roman effect license eisai elect obtain reversion described section nbsp below license granted epizyme under section nbsp shall terminated further force effect whether eisai elect obtain such reversion license granted eisai under section nbsp shall survive remain full force effect provided that such license under section nbsp shall limited epizyme collaboration joint each case controlled epizyme effective date termination used effective date termination development manufacture commercialization licensed compound licensed product they exist date termination eisai elect obtain reversion described section nbsp below license granted epizyme under section nbsp this agreement shall survive remain full force effect provided that such license under section nbsp shall limited eisai collaboration joint each case controlled eisai effective date termination used effective date termination development manufacture commercialization licensed compound licensed product they exist date termination style margin margin bottom text indent font size font family time roman reversion option eisai shall have right elect pursuant written notice provided epizyme before later nbsp date that after effective date such termination nbsp date that after epizyme provides report required section nbsp provision forth section through become effective style margin margin bottom text indent font size font family time roman license grant eisai effective upon such termination eisai elect obtain such license accordance with section nbsp epizyme hereby grant eisai perpetual irrevocable royalty bearing forth section nbsp exclusive right license even epizyme affiliate with right grant sublicenses under epizyme collaboration joint each case controlled epizyme effective date termination used effective date termination development manufacture commercialization licensed compound licensed product they exist date termination solely continue develop manufacture commercialize such licensed compound licensed product field epizyme territory provided that style margin margin bottom text indent font size font family time roman foregoing license shall exclude license other right with respect therapeutically active pharmaceutical ingredient that licensed compound which covered patent controlled epizyme affiliate style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman epizyme shall provide eisai with copy third party agreement with respect epizyme epizyme collaboration that subject license granted epizyme eisai pursuant this section nbsp eisai time thereafter exclude epizyme epizyme collaboration that subject such third party agreement from grant forth this section nbsp written notice epizyme which event clause nbsp below shall apply thereafter such third party agreement eisai shall have obligation with respect amount that become payable under such third party agreement style margin margin bottom text indent font size font family time roman eisai shall responsible nbsp making payment including royalty milestone other amount payable epizyme third party under such third party agreement that applicable grant eisai such license exercise such license eisai affiliate sublicensees making such payment directly epizyme each instance eisai shall make requisite payment epizyme provide necessary reporting information epizyme sufficient time enable epizyme comply with obligation under such third party agreement nbsp complying with other obligation included such third party agreement that applicable grant eisai such license exercise such license eisai affiliate sublicensees provided that epizyme shall solely responsible shall amount payable under license agreement under other agreement entered into epizyme affiliate style margin margin bottom text indent font size font family time roman epizyme shall responsible paying providing such third party payment report made provided eisai under this section nbsp style margin margin bottom text indent font size font family time roman manufacturing upon eisai request epizyme shall part transition plan mutually agreed party under clause nbsp below eisai expense transfer eisai designee process document material other know extent foregoing controlled epizyme effective date termination used manufacture licensed product field they exist date termination provided that upon eisai request pursuant supply agreement negotiated good faith party purchase price equal epizyme cost good clinical supply epizyme cost good commercial supply supply eisai with clinical commercial quantity licensed product epizyme territory dosage strength formulation presentation under development being commercialized epizyme either case effective date termination until earlier nbsp month after effective date termination nbsp establishment eisai alternative supply such licensed product commercially reasonable term style margin margin bottom text indent font size font family time roman prosecution enforcement provision article shall terminated except section nbsp addition between party eisai shall have right obligation prosecute maintain enforce epizyme collaboration patent that primarily applicable compound licensed eisai pursuant style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman clause nbsp above under same term same extent epizyme right prosecute maintain enforce epizyme collaboration patent under article during term epizyme shall provide such assistance cooperation reasonably necessary connection with transition prosecution enforcement responsibility eisai with respect such epizyme collaboration patent including execution such document necessary effect such transition style margin margin bottom text indent font size font family time roman other provision style margin margin bottom text indent font size font family time roman effect termination forth section nbsp above shall apply mutatis mutandis with eisai being substituted epizyme epizyme being substituted eisai style margin margin bottom text indent font size font family time roman date termination none epizyme affiliate sublicensees been awarded connection with licensed product then provision section nbsp priority review voucher shall apply mutatis mutandis with eisai being substituted epizyme epizyme being substituted eisai style margin margin bottom text indent font size font family time roman date termination epizyme affiliate sublicensee been awarded connection with licensed product such been redeemed transferred third party epizyme affiliate sublicensee then nbsp within after eisai election obtain reversion described section nbsp epizyme shall shall cause applicable affiliate sublicensee assign convey transfer eisai right title interest such additional consideration nbsp after such transfer provision section nbsp priority review voucher shall apply mutatis mutandis with eisai being substituted epizyme epizyme being substituted eisai style margin margin bottom text indent font size font family time roman date termination epizyme affiliate sublicensee been awarded connection with licensed product such been redeemed transferred third party epizyme affiliate sublicensee then provision section nbsp priority review voucher shall survive accordance with their term style margin margin bottom text indent font size font family time roman royalty style margin margin bottom text indent font size font family time roman subject section mutatis mutandis eisai shall epizyme style margin margin bottom text indent font size font family time roman royalty sale each therapeutic product japan during royalty term such therapeutic product japan therapeutic product therapeutic product basis style margin margin bottom text indent font size font family time roman either style margin margin bottom text indent font size font family time roman eisai terminates this agreement with respect epizyme territory pursuant section nbsp eisai terminates this agreement style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman entirety pursuant section nbsp royalty sale each therapeutic product each country during royalty term such therapeutic product such country therapeutic product therapeutic product country country basis royalty rate forth table below style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width style font family time roman font size valign bottom style margin margin bottom font size font family time roman sale style margin margin bottom font size font family time roman each therapeutic product each country valign bottom nbsp nbsp valign bottom colspan align center incremental royalty nbsp rate valign bottom nbsp bgcolor cceeff style font family time roman font size valign style margin left text indent font size font family time roman portion including valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp style font size height height colspan style font family time roman font size valign style margin left text indent font size font family time roman portion greater than valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp table style margin margin bottom font size font family time roman clarity royalty tier forth table above shall apply separately each separate therapeutic product each country example nbsp sale over applicable royalty term country therapeutic product sale over applicable royalty term country therapeutic product then such sale country both therapeutic product therapeutic product shall bear royalty rate nbsp sale over applicable royalty term country therapeutic product have exceeded then sale country therapeutic product including shall bear royalty rate sale country therapeutic product excess shall bear royalty rate remainder royalty term therapeutic product country nbsp sale over applicable royalty term country therapeutic product have exceeded sale country therapeutic product then sale country over applicable royalty term therapeutic product excess shall bear royalty rate remainder royalty term therapeutic product country sale country therapeutic product shall bear royalty rate until sale country therapeutic product reach after which sale country therapeutic product shall bear royalty rate remainder royalty term therapeutic product country style margin margin bottom margin left text indent font size font family time roman epizyme terminates this agreement with respect epizyme territory pursuant section nbsp including deemed termination pursuant section nbsp royalty percent annual sale each therapeutic product each country during royalty term such therapeutic product such country therapeutic product therapeutic product basis style margin margin bottom text indent font size font family time roman provision section mutatis mutandis shall apply eisai royalty payment obligation under section style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman development cost style margin margin bottom text indent font size font family time roman date termination licensed product achieved regulatory approval united state major country through centralized approval procedure indication then style margin margin bottom text indent font size font family time roman eisai shall reimburse epizyme amount equal percent development cost incurred epizyme performing activity connection with development licensed compound licensed product hereunder during period beginning restatement date ending date termination which amount shall payable eisai equal installment later than first business each first calendar quarter occurring after date eisai election pursuant section nbsp style margin margin bottom text indent font size font family time roman only licensed product achieves regulatory approval united state major country through centralized approval procedure indication after date termination eisai shall reimburse epizyme amount equal percent development cost incurred epizyme performing activity connection with development licensed compound licensed product hereunder during period beginning restatement date ending date termination which amount shall payable eisai equal installment later than first business each first calendar quarter occurring after date first such regulatory approval style margin margin bottom text indent font size font family time roman date termination least achieved regulatory approval united state major country through centralized approval procedure indication then eisai shall reimburse epizyme amount equal incurred epizyme performing activity connection with development licensed compound licensed product hereunder during period beginning restatement date ending date first such regulatory approval which amount shall payable eisai equal installment later than first business each first calendar quarter occurring after date eisai election pursuant section nbsp style margin margin bottom text indent font size font family time roman eisai shall during three year period following eisai election pursuant section nbsp have right have epizyme book record relating development cost reimbursable hereunder audited pursuant term section applied this section nbsp mutatis mutandis style margin margin bottom text indent font size font family time roman damage offset event eisai validly elect exercise reversion option described under section nbsp such option arose under section nbsp then without limiting applicability section nbsp eisai make claim damage against epizyme following such reversion epizyme shall entitled offset against damage which eisai would otherwise entitled equal defined below eisai make such claim damage then party shall within business date such claim engage reputable investment banker mutually agreeable party with agreement unreasonably withheld delayed with expertise biotechnology pharmaceutical industry perform monetary valuation right license granted otherwise transferred eisai under section through each party shall payable style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman report development cost later than thirty after date termination epizyme shall provide eisai written report development cost incurred epizyme performing activity connection with development licensed compound licensed product hereunder during period beginning restatement date ending date termination which report shall reasonable detail together with reasonable evidence supporting such development cost style margin margin bottom text indent font size font family time roman reversion avoidance doubt provision section through shall force effect unless until eisai make valid election that effect specified under section nbsp eisai make such election accordance with section nbsp then style margin margin bottom text indent font size font family time roman epizyme obligation eisai right under article shall survive such termination including clarity epizyme ceased development commercialization licensed compound licensed product date such termination epizyme affiliate restart development commercialization licensed compound licensed product after date such termination style margin margin bottom text indent font size font family time roman event that epizyme affiliate sell otherwise transfer third party ownership asset relating licensed compound licensed product epizyme territory transaction that involve assignment assumption such third party epizyme right obligation under this agreement pursuant section nbsp such third party shall agree condition such sale transfer fully assume obligation epizyme forth section nbsp each case such obligation relate such asset purported sale transfer asset transaction described above this section nbsp that include such assumption obligation shall null void style margin margin bottom text indent font size font family time roman this agreement party right obligation with respect eisai territory shall remain full force effect style margin margin bottom text indent font size font family time roman payment obligation payment obligation that have accrued that have been satisfied prior date such termination shall survive style margin margin bottom text indent font size font family time roman accrued right surviving provision style margin margin bottom text indent font size font family time roman termination expiration this agreement reason shall without prejudice right that shall have accrued benefit party prior such termination expiration including payment obligation under article hereof damage remedy arising from breach hereunder such termination expiration shall relieve party from obligation which expressly indicated survive termination this agreement style margin margin bottom text indent font size font family time roman provision section article extent definition required interpret surviving provision this agreement extent amount unpaid effective date termination extent provision article relate payment obligation that otherwise style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman survive pursuant section nbsp accordance with term shall survive termination this agreement entirety expiration this agreement applicable accordance with their respective term condition duration stated where duration stated shall survive indefinitely article shall survive period year after effective date termination expiration this agreement style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center miscellaneous style margin margin bottom text indent font size font family time roman dispute resolution except with respect dispute described section nbsp section nbsp dispute matter within authority which shall determined accordance with section nbsp section nbsp section nbsp respectively which shall subject this section nbsp purpose clarity neither shall such dispute subject arbitration pursuant section nbsp dispute between party arises under this agreement either party shall have right refer such dispute writing respective executive officer such executive officer shall attempt good faith resolve such dispute executive officer unable resolve given dispute pursuant this section nbsp within after referring such dispute executive officer either party have given dispute settled binding arbitration pursuant section nbsp style margin margin bottom text indent font size font family time roman arbitration request party intends begin arbitration resolve dispute arising under this agreement such party shall provide written notice arbitration request other party such intention statement issue resolution from date arbitration request until such time dispute become finally settled running time period which other party must cure breach this agreement becomes suspended breach that subject matter dispute style margin margin bottom text indent font size font family time roman additional issue within after receipt arbitration request other party written notice additional issue resolution statement counter issue style margin margin bottom text indent font size font family time roman arbitration patent issue dispute controversy claim relating scope validity enforceability infringement inventorship ownership patent shall submitted court competent jurisdiction country which such patent right apply style margin margin bottom text indent font size font family time roman arbitration procedure arbitration pursuant this article will held york york united state unless another location mutually agreed party arbitration will governed united state arbitration nbsp exclusion inconsistent state party shall mutually agree rule govern discovery rule evidence arbitration within after arbitration request party fail timely agree such rule united state federal rule civil procedure will govern discovery united state federal rule evidence will govern evidence arbitration arbitration will conducted single arbitrator knowledgeable subject matter issue dispute acceptable both party provided that party mutual agreement elect have arbitration conducted panel three nbsp arbitrator party fail agree mutually acceptable arbitrator style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman within after arbitration request then arbitrator shall selected york york office arbitrator proceed award notwithstanding failure either party participate proceeding arbitrator shall within after conclusion arbitration hearing issue written award statement decision describing essential finding conclusion which award based including calculation damage awarded arbitrator shall limited scope authority resolving only specific matter which party have referred arbitration resolution shall have authority render decision award other issue subject section nbsp arbitrator shall authorized award compensatory damage shall authorized award punitive special consequential other similar form damage reform modify materially change this agreement arbitrator also shall authorized grant temporary preliminary permanent equitable remedy relief arbitrator deems just equitable within scope this agreement including injunction order specific performance party hereby expressly agree waive right appeal from decision arbitrator there shall appeal court other authority government private from decision arbitrator judgment award rendered arbitrator enforced court having competent jurisdiction thereof subject only revocation award ground forth united nation convention recognition enforcement foreign arbitral award style margin margin bottom text indent font size font family time roman cost each party shall bear attorney cost disbursement arising arbitration shall equal share cost arbitrator style margin margin bottom text indent font size font family time roman preliminary injunction notwithstanding anything this agreement contrary party seek temporary restraining order preliminary injunction from court competent jurisdiction order prevent immediate irreparable injury loss damage provisional basis pending award arbitrator ultimate merit dispute style margin margin bottom text indent font size font family time roman confidentiality proceeding decision arbitrator shall deemed confidential information each party shall subject article style margin margin bottom text indent font size font family time roman governing this agreement dispute arising from performance breach hereof shall governed construed enforced accordance with state york excluding conflict choice rule principle that might otherwise refer construction interpretation this agreement substantive another jurisdiction provision united nation convention contract international sale good shall apply this agreement subject matter hereof style margin margin bottom text indent font size font family time roman assignment neither party assign this agreement without consent other party except otherwise provided this section nbsp either party assign this agreement whole part affiliate such party without consent other party provided that such assigning party provides other party with written notice such assignment affiliate agrees writing assume performance assigned obligation assigning party shall remain primarily liable performance obligation under this agreement such affiliate further each party assign this agreement style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman right obligation hereunder without consent other party successor interest merger consolidation connection with sale substantially business asset which this agreement relates event such assignment assigning party shall provide other party with written notice such assignment assignee shall required agree writing assume performance assigned obligation provided that change control event described section nbsp occurs assigning party shall required assign this agreement right obligation hereunder acquiror substantially such party business asset which this agreement relates such assignee shall required agree with other party writing assume performance assigned obligation purported assignment violation this section nbsp shall null void style margin margin bottom text indent font size font family time roman performance warranty each party hereby acknowledges agrees that shall responsible full timely performance when under observance covenant term condition agreement forth this agreement affiliate sublicensees style margin margin bottom text indent font size font family time roman force majeure party shall held liable responsible other party deemed default under breach provision this agreement failure delay fulfilling performing obligation other than payment obligation this agreement when such failure delay force majeure without fault negligence party failing delaying purpose this agreement force majeure defined cause beyond control party including material change civil commotion destruction production facility material fire flood earthquake explosion storm labor disturbance epidemic failure public utility common carrier such event epizyme eisai case shall immediately notify other party such inability period which such inability expected continue party giving such notice shall thereupon excused from such obligation under this agreement thereby disabled from performing long disabled maximum ninety nbsp after which time epizyme eisai shall promptly meet discus good faith best proceed manner that maintains abides agreement extent possible each party shall reasonable effort minimize duration force majeure style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman notice notice request required permitted given under connection with this agreement shall deemed have been sufficiently given writing personally delivered sent facsimile transmission receipt verified international overnight express courier service signature required prepaid party which such notice intended address forth such party below style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width style font family time roman font size valign colspan epizyme style font size height height colspan style font family time roman font size valign addressed valign bottom valign colspan epizyme style font family time roman font size valign valign bottom valign colspan technology drive floor style font family time roman font size valign valign bottom valign colspan cambridge massachusetts style font family time roman font size valign valign bottom valign colspan attention chief executive officer style font family time roman font size valign valign bottom valign colspan telephone style font family time roman font size valign valign bottom valign colspan facsimile style font size height height colspan style font family time roman font size valign with copy valign bottom valign colspan wilmerhale style font family time roman font size valign valign bottom valign colspan state street style font family time roman font size valign valign bottom valign colspan boston style font family time roman font size valign valign bottom valign attention valign bottom valign stuart falber style font family time roman font size valign valign bottom valign valign bottom valign steven barrett style font family time roman font size valign valign bottom valign telephone valign bottom valign style font family time roman font size valign valign bottom valign facsimile valign bottom valign style font size height height colspan style font family time roman font size valign eisai valign bottom colspan valign style font size height height colspan style font family time roman font size valign addressed valign bottom valign colspan eisai style font family time roman font size valign valign bottom valign colspan koishikawa style font family time roman font size valign valign bottom valign colspan bunkyo style font family time roman font size valign valign bottom valign colspan tokyo style font family time roman font size valign valign bottom valign colspan japan style font family time roman font size valign valign bottom valign attention valign bottom valign chief product creation officer style font family time roman font size valign valign bottom valign telephone valign bottom valign style font family time roman font size valign valign bottom valign facsimile valign bottom valign style font size height height colspan style font family time roman font size valign with copy valign bottom valign colspan eisai style font family time roman font size valign valign bottom valign colspan koishikawa style font family time roman font size valign valign bottom valign colspan bunkyo style font family time roman font size valign valign bottom valign colspan tokyo style font family time roman font size valign valign bottom valign colspan japan style font family time roman font size valign valign bottom valign attention valign bottom valign general counsel style font family time roman font size valign valign bottom valign telephone valign bottom valign style font family time roman font size valign valign bottom valign facsimile valign bottom valign style font size height height colspan style font family time roman font size valign style text indent font size font family time roman valign bottom valign colspan eisai style font family time roman font size valign valign bottom valign colspan tice blvd style font family time roman font size valign valign bottom valign colspan woodcliff lake style font family time roman font size valign valign bottom valign attention valign bottom valign president style font family time roman font size valign valign bottom valign valign bottom valign general counsel style font family time roman font size valign valign bottom valign telephone valign bottom valign style font family time roman font size valign valign bottom valign facsimile valign bottom valign table style margin margin bottom font size font family time roman such other address such party shall have specified like notice other party provided that notice change address shall effective only upon receipt thereof delivered personally facsimile transmission date delivery shall deemed style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman which such notice request given such business first business thereafter sent overnight express courier service date delivery shall deemed second business after such notice request deposited with such service style margin margin bottom text indent font size font family time roman export clause each party acknowledges that united state restrict export export certain commodity technical data united state origin each party agrees that will export export restricted commodity technical data other party form without appropriate united state foreign government license style margin margin bottom text indent font size font family time roman waiver neither party waive release right interest this agreement except writing failure either party assert right hereunder insist upon compliance with term this agreement shall constitute waiver that right excuse similar subsequent failure perform such term condition waiver either party condition term more instance shall construed continuing waiver such condition term another condition term right remedy provided herein cumulative exclude other right remedy provided otherwise available except expressly forth herein style margin margin bottom text indent font size font family time roman severability provision hereof should held invalid illegal unenforceable jurisdiction otherwise directly indirectly affect validity other material provision this agreement severed clause other provision hereof shall remain full force effect such jurisdiction except such severed clause such invalidity illegality unenforceability shall affect validity legality enforceability such provision other jurisdiction party shall consult good faith effort agree upon valid enforceable provision which shall reasonable substitute such severed clause light intent this agreement style margin margin bottom text indent font size font family time roman entire agreement this agreement together with exhibit hereto thereto existing agreement amended letter agreement forth covenant promise agreement warranty representation condition understanding between party with respect subject matter this agreement existing agreement amended letter agreement supersede terminate prior agreement understanding between party with respect subject matter this agreement existing agreement amended letter agreement particular without limitation this agreement supersedes replaces existing confidentiality agreement term sheet relating transaction contemplated this agreement exchanged between party prior restatement date there covenant promise agreement warranty representation condition understanding either oral written between party with respect subject matter this agreement other than forth herein therein subsequent alteration amendment change addition this agreement shall binding upon party unless reduced writing signed respective authorized officer party style margin margin bottom text indent font size font family time roman independent contractor nothing herein shall construed create relationship employer employee agent principal partnership joint venture between style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman party each party independent contractor neither party shall assume either directly indirectly liability other party neither party shall have authority bind obligate other party neither party shall represent that such authority style margin margin bottom text indent font size font family time roman solicitation employee during period commencing restatement date ending upon termination expiration this agreement with respect eisai territory neither party shall solicit employee leave employment other party accept employment work consultant with soliciting party notwithstanding foregoing nothing herein shall restrict preclude either party right make generalized search employee general solicitation employment placed trade journal newspaper website purpose this section nbsp employee mean employee material performance collaboration hereunder including member subcommittee thereof style margin margin bottom text indent font size font family time roman heading construction interpretation heading used herein convenience only shall affect construction taken into consideration interpreting this agreement term this agreement represent result negotiation between party their representative each which been represented counsel choosing neither which acted under duress compulsion whether legal economic otherwise accordingly term this agreement shall interpreted construed accordance with their usual customary meaning each party hereto hereby waif application connection with interpretation construction this agreement rule effect that ambiguous conflicting term provision contained this agreement shall interpreted construed against party whose attorney prepared executed draft earlier draft this agreement reference this agreement article section subsection paragraph clause exhibit shall deemed reference article section subsection paragraph clause exhibit case this agreement except where context otherwise requires nbsp definition reference agreement instrument other document refers such agreement instrument other document from time time amended supplemented otherwise modified subject restriction such amendment supplement modification forth herein therein nbsp reference refers such from time time enacted repealed amended nbsp word herein hereof hereunder word similar import refer this agreement entirety particular provision hereof nbsp word include includes including shall deemed followed phrase limited without limitation word similar import nbsp nbsp word used inclusive sense nbsp singular shall include plural plural singular gender shall applicable gender style margin margin bottom text indent font size font family time roman book record financial book record maintained under this agreement party affiliate sublicensees shall maintained accordance with accounting principle customarily used such person applicable country gaap consistently applied except that same need audited style margin margin bottom text indent font size font family time roman further action each party shall execute acknowledge deliver such further instrument such other necessary appropriate order carry expressly stated purpose clear intent this agreement style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman party interest term provision this agreement shall binding upon shall inure benefit enforceable party hereto their respective successor permitted assigns covenant agreement forth this agreement sole benefit party their successor permitted assigns with respect indemnification under article indemnitees identified thereunder they shall construed conferring right other person style margin margin bottom text indent font size font family time roman performance affiliate extent that this agreement imposes obligation affiliate party such party agrees cause affiliate perform such obligation style margin margin bottom text indent font size font family time roman counterpart this agreement signed counterpart each every which shall deemed original notwithstanding variation format file designation which result from electronic transmission storage printing copy from separate computer printer facsimile signature signature transmitted shall treated original signature style margin margin bottom text indent font size font family time roman amendment restatement novation this agreement constitutes amendment restatement prior agreement effective from after restatement date execution delivery this agreement shall constitute novation right obligation owing under prior agreement based fact event occurring existing prior restatement date restatement date prior agreement hereby amended supplemented modified restated entirety described herein style margin margin bottom font size font family time roman align center signature page follow style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman witness whereof intending legally bound hereby party have caused this agreement executed their duly authorized representative restatement date style font size margin margin bottom nbsp align right table cellspacing cellpadding width border style border collapse collapse font family time roman font size width valign bottom width width valign bottom width width style font family time roman font size valign colspan epizyme style font size height height colspan style font family time roman font size valign valign bottom valign colspan style margin margin bottom border bottom solid font size font family time roman robert gould style font family time roman font size valign valign bottom valign name valign bottom valign robert gould style font family time roman font size valign valign bottom valign title valign bottom valign president style font size height colspan style font family time roman font size valign colspan eisai style font size height height colspan style font family time roman font size valign valign bottom valign colspan style margin margin bottom border bottom solid font size font family time roman hideki hayashi style font family time roman font size valign valign bottom valign name valign bottom valign hideki hayashi style font family time roman font size valign valign bottom valign title valign bottom valign representative corporate officer corporate planning strategy chief information officer table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman align center epizyme patent style margin margin bottom font size font family time roman align center restatement date style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center valign bottom width valign bottom width valign bottom width valign bottom width valign bottom width valign bottom width valign bottom width valign bottom width valign bottom width valign bottom width valign bottom width style font family time roman font size valign bottom nowrap align center style border bottom solid width font size font family time roman align center origin valign bottom nbsp valign bottom nowrap align center style border bottom solid width font size font family time roman align center country valign bottom nbsp valign bottom nowrap align center style border bottom solid width font size font family time roman align center title valign bottom nbsp valign bottom nowrap align center style border bottom solid width font size font family time roman align center inventor nbsp list valign bottom nbsp valign bottom nowrap align center style border bottom solid width font size font family time roman align center appl status valign bottom nbsp valign bottom nowrap align center style border bottom solid width font size font family time roman align center serial number valign bottom nbsp valign bottom nowrap align center style border bottom solid width font size font family time roman align center filing nbsp date valign bottom nbsp valign bottom nowrap align center style border bottom solid width font size font family time roman align center publication number valign bottom nbsp valign bottom nowrap align center style border bottom solid width font size font family time roman align center publication date valign bottom nbsp valign bottom nowrap align center style border bottom solid width font size font family time roman align center patent number valign bottom nbsp valign bottom nowrap align center style border bottom solid width font size font family time roman align center issue nbsp date valign bottom nbsp valign bottom nowrap align center style border bottom solid width font size font family time roman align center expiration date bgcolor cceeff style font family time roman font size valign valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom style font family time roman font size valign valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom bgcolor cceeff style font family time roman font size valign valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom valign bottom nbsp valign bottom table style margin margin bottom font size font family time roman confidential material omitted filed separately with security exchange commission total seven page were omitted style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman align center transition matter style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign clinical valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign epizyme will reimburse eisai external cost with current estimated cost style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign epizyme will reimburse eisai internal cost rate month during transition actual duration determined epizyme total estimated style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign letter sent biotrials later than after execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign document will provided later than after execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign eisai will provide facilitate assistance with transition epizyme epizyme later than valign bottom nbsp valign epizyme will reimburse eisai internal cost rate month month during transition total estimated support rate month month total estimated during transition determined epizyme epizyme will reimburse eisai internal cost rate month determined necessary epizyme total cost currently anticipated style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign copy will provided epizyme within execution agreement valign bottom nbsp valign none table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign upon execution epizyme provide assistance following transfer completion valign bottom nbsp valign epizyme will reimburse eisai internal cost rate month month during transition estimated total following transition estimated total each case determined necessary epizyme style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign upon execution epizyme provide assistance following transfer completion valign bottom nbsp valign included item style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign upon execution epizyme valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign document existing completion will added within additional document generated during transition will added within document creation valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign eisai will fully support valign bottom nbsp valign epizyme will reimburse eisai external cost with upon assignment epizyme will reimburse eisai internal cost rate month month during transition estimated total rate month month estimated total during transition determined epizyme epizyme will reimburse eisai internal cost rate month month estimated total determined epizyme style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign upon execution agreement mutually agreeable time needed upon request from epizyme during through valign bottom nbsp valign none table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign confirmation complete list receipt copy completed within executing agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign through completion assigned eisai epizyme upon party mutual agreement valign bottom nbsp valign epizyme will reimburse eisai external cost with after execution restated agreement then assume additional cost payment after execution epizyme eisai assignment assignment reimbursement epizyme actual invoice received eisai from current estimated cost month estimated style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign letter sent later than after execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign complete provided epizyme within execution agreement sample transferred epizyme later than upon regulatory approval epizyme valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign after approval valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign will maintained eisai until epizyme assumes regulatory control study valign bottom nbsp valign epizyme reimburse eisai invoiced cost from prior epizyme assuming coverage estimated cost style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign promptly after epizyme assumes valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign eisai will confirm version upon execution agreement facilitate within epizyme execution contract valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign least from execution agreement through additional thereafter allow epizyme valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign eisai will send epizyme review upon execution agreement will sent eisai with epizyme contact copied within execution agreement valign bottom nbsp valign none table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign upon execution agreement through epizyme valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign word document final valign bottom nbsp valign within execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within post execution valign bottom nbsp valign none table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign regulatory valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign initiated after valign bottom nbsp valign epizyme will reimburse eisai internal cost regulatory support rate month month during transition total estimated cost determined epizyme style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign will performed provided valign bottom nbsp valign epizyme will reimburse eisai internal cost data management support rate month duration determined epizyme style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement valign bottom nbsp valign none none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign word document final valign bottom nbsp valign within execution agreement valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement valign bottom nbsp valign none table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign received with epizyme approval confirmation within execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign completed shipment indicated below valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement valign bottom nbsp valign plus cost shipping import consumer style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign received with epizyme approval confirmation within execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign received with epizyme approval confirmation within execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than following date execution agreement valign bottom nbsp valign preparing summary style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign received with epizyme approval confirmation within execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign received with epizyme approval confirmation within execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than date execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign document provided previously receipt confirmed epizyme within execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than following date execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than following date execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than following date execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign received with epizyme approval confirmation within execution agreement valign bottom nbsp valign none table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign received with epizyme approval confirmation within execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign shipped epizyme designee within confirmation epizyme designated recipient receipt email request valign bottom nbsp valign based gram drug substance gram plus cost shipping import consumer style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign shipped epizyme designee within confirmation epizyme designated recipient receipt email request valign bottom nbsp valign style margin margin bottom font size font family time roman available gram total style font size margin margin bottom nbsp style margin margin bottom font size font family time roman marker style font size margin margin bottom nbsp style margin margin bottom font size font family time roman style font size margin margin bottom nbsp style margin margin bottom font size font family time roman gram total style font size margin margin bottom nbsp style margin margin bottom font size font family time roman plus cost shipping import consumer style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign later than following execution agreement pending identification epizyme designated recipient pending government approval shipment valign bottom nbsp valign plus documentation cost shipping import consumer style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign shipped transfer ownership epizyme within epizyme execution contract with valign bottom nbsp valign plus cost shipping import consumer when payment required authority style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign agreed valign bottom nbsp valign preparing summary report style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign agreed later than valign bottom nbsp valign preparing report style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than following date execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than following date execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than following date execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign shipped epizyme designee later than valign bottom nbsp valign invoiced under number provided epizyme table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign shipped epizyme designee within confirmation epizyme designated recipient receipt email request with instruction valign bottom nbsp valign gram based actual amount available plus cost shipping import consumer style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign shipped epizyme designee within confirmation epizyme designated recipient receipt email request with instruction valign bottom nbsp valign plus cost shipping import consumer style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign ownership transferred upon valign bottom nbsp valign epizyme will reimburse cost current stocked tablet cost quote cost invoiced epizyme style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign later than valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign received with acknowledged epizyme later than following execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign later than valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign later than valign bottom nbsp valign copy preparation invoiced rate style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than following date execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign later than following execution agreement valign bottom nbsp valign ftes documentation style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within epizyme request following execution agreement event later than following execution agreement valign bottom nbsp valign plus cost shipping import consumer style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign after stability study valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign estimated delivery date valign bottom nbsp valign through cost material invoiced dollar including eisai tech transfer cost rate subject approval epizyme cost plus cost shipping import consumer style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign tentative valign bottom nbsp valign cost based eisai epizyme agreed confirm actual estimated price style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign starting after execution agreement until valign bottom nbsp valign epizyme will reimburse eisai internal external cost based epizyme request basis internal cost will calculated using table style line height margin margin bottom border bottom solid width nbsp style margin margin bottom font size font family time roman style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than following execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than following date execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than following date execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than following date execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than following date execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than following date execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than following date execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than following date execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than following date execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within epizyme request following execution agreement event later than following execution agreement valign bottom nbsp valign style margin margin bottom font size font family time roman based available gram plus style margin margin bottom font size font family time roman cost shipping import consumer style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than following date execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign provided later than following date execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within following execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within following execution agreement valign bottom nbsp valign none table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within following execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within following execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within following execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within following execution agreement pending confirmation epizyme designated recipient valign bottom nbsp valign based gram plus cost shipping import consumer style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within following execution agreement valign bottom nbsp valign gram plus cost shipping import consumer style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within following execution agreement pending confirmation epizyme designated recipient valign bottom nbsp valign gram plus cost shipping import consumer style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within following execution agreement valign bottom nbsp valign gram plus cost shipping import consumer style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign copy preparation invoiced rate style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign starting after execution until valign bottom nbsp valign epizyme will reimburse eisai internal external cost based epizyme request basis internal cost will calculated table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign preclinical biology valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign rowspan valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign rowspan valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign hard drive shipping style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign rowspan valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign rowspan valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign shipping style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign rowspan valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign shipping reimbursed style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign shipping reimbursed style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign rowspan valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign none style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign rowspan valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign shipping reimbursed style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign rowspan valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign shipping style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign rowspan valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign rowspan valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign none style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign rowspan valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign nonclinical dmpk valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign rowspan valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font family time roman font size valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within receipt final study report from valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within execution agreement upon epizyme request send epizyme designated archive site valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution upon epizyme request send epizyme designated archive site valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution upon epizyme request send epizyme designated archive site valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution upon epizyme request send epizyme designated archive site valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign shipping reimbursed table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign following execution agreement valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign intentionally blank valign bottom nbsp valign intentionally blank valign bottom nbsp valign intentionally blank style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign intentionally blank valign bottom nbsp valign intentionally blank valign bottom nbsp valign intentionally blank table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign translational medicine valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign epizyme will reimburse eisai internal cost performance monthly rate month month determined epizyme epizyme will reimburse eisai month complete epizyme will reimburse through cost associated with style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign epizyme will reimburse eisai internal cost monthly rate month month determined needed epizyme epizyme will reimburse eisai month complete epizyme will reimburse through cost associated with style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign upon execution valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign upon execution valign bottom nbsp valign shipping reimbursed style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign upon execution valign bottom nbsp valign shipping reimbursed style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign upon execution valign bottom nbsp valign shipping reimbursed style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign upon execution valign bottom nbsp valign shipping reimbursed style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign upon execution valign bottom nbsp valign shipping reimbursed style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign upon execution valign bottom nbsp valign shipping reimbursed style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign upon execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign upon execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman deliverable performance requirement valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman duration completion deadline valign bottom nbsp valign bottom nowrap style border bottom solid width font size font family time roman cost associated style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign upon execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign upon execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign upon execution valign bottom nbsp valign none style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign clinical database style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign upon execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign upon execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign upon execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign within agreement execution valign bottom nbsp valign none table style margin margin bottom font size font family time roman except forth below proviso liability third party accrued eisai prior restatement date agreement borne eisai style margin margin bottom font size font family time roman extent third party liability agreed assumed epizyme herein epizyme only responsible liability accrued beginning restatement date agreement provided however that milestone based payment scheduled payment based regular timing interval which have become payable prior restatement date agreement shall borne solely epizyme style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman extent party transfer material between them connection with transfer transitional activity party shall document such transfer writing through customary material transfer documentation style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman align center epizyme press release style margin margin bottom font size font family time roman align center epizyme reacquires global right from eisai first class inhibitor style margin margin bottom font size font family time roman align center epizyme obtains global operational responsibility exclusive worldwide commercial right outside japan style margin margin bottom font size font family time roman cambridge mass march nbsp epizyme nasdaq epzm clinical stage biopharmaceutical company creating novel epigenetic therapeutic cancer patient announced today that reacquired global right program including font style white space nowrap font from partner eisai under term agreement epizyme will solely responsible global clinical development manufacturing commercialization country outside japan where eisai will retain right font style white space nowrap first class font inhibitor currently being evaluated phase clinical study treatment cell hodgkin lymphoma deficient solid tumor such synovial sarcoma malignant rhabdoid tumor style margin margin bottom font size font family time roman over past seven year have been deliberately building epizyme independent fully integrated oncology company obtaining global control very promising clinical asset represents important milestone evolution company said robert gould president chief executive officer epizyme began quality duration response including complete response relapsed refractory deficient patient treated with font style white space nowrap font monotherapy became clear that having worldwide development commercialization responsibility targeted therapeutic like would transformative epizyme style margin margin bottom font size font family time roman with continued emergence clinical data apparent that this therapy with tremendous potential benefit variety patient population said takashi chief innovation officer eisai product creation system font style white space nowrap focus font resource later stage program across therapeutic area believe that epizyme well positioned move font style white space nowrap font development forward aggressively pleased that structure this agreement allows participate future success style margin margin bottom font size font family time roman following completion transition from eisai epizyme epizyme plan conduct font style white space nowrap five font phase study approximately patient with hodgkin lymphoma this study will evaluate following patient cohort style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left width valign nbsp align left valign diffuse large cell lymphoma germinal center cell like type with wild type table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left width valign nbsp align left valign diffuse large cell lymphoma type with mutant table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left width valign nbsp align left valign follicular lymphoma with wild type table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left width valign nbsp align left valign follicular lymphoma with mutant table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left width valign nbsp align left valign diffuse large cell lymphoma type table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman cohort patient with diffuse large cell type expected include predominantly patient with wild type since frequency mutation approximately this population diffuse large cell lymphoma style margin margin bottom font size font family time roman addition epizyme plan initiate phase study adult with deficient tumor including synovial sarcoma phase study child with deficient tumor including malignant rhabdoid tumor epizyme will also continue clinical pharmacology study that part eisai epizyme clinical plan style margin margin bottom font size font family time roman pleased lead development look forward further exploring defining clinical activity safety range hematological solid tumor indication said peter chief development officer epizyme style margin margin bottom font size font family time roman term agreement style margin margin bottom font size font family time roman under term agreement epizyme will responsible global development manufacturing commercialization epizyme will fund percent global development cost eisai will fund percent japan specific development cost style margin margin bottom font size font family time roman epizyme will make million upfront payment eisai with total million potential clinical milestone payment million potential regulatory milestone payment epizyme will eisai royalty percentage teen sale outside japan eisai will epizyme royalty percentage teen sale japan eisai will have limited right first negotiation asia right epizyme decides license asia right third party style margin margin bottom font size font family time roman conference call information style margin margin bottom font size font family time roman company will discus detail this transaction company development plan financial result conference call held today march nbsp style margin margin bottom font size font family time roman participate conference call please dial domestic international refer conference live webcast accessed under event presentation investor relation section company website nbsp epizyme style margin margin bottom font size font family time roman about style margin margin bottom font size font family time roman epizyme developing treatment hodgkin lymphoma patient patient with deficient solid tumor small molecule inhibitor developed epizyme many human cancer misregulated enzyme activity result misregulation gene that control cell proliferation without these control mechanism cancer cell free grow rapidly style margin margin bottom font size font family time roman second hmti enter human clinical development following epizyme inhibitor style margin margin bottom font size font family time roman additional information about this program including clinical trial information found here http clinicaltrials show term rank style margin margin bottom font size font family time roman about epizyme style margin margin bottom font size font family time roman epizyme clinical stage biopharmaceutical company creating novel epigenetic therapeutic cancer patient epizyme built proprietary product platform that company create small molecule inhibitor member class enzyme known style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman histone methyltransferases hmts hmts part system gene regulation referred epigenetics that control gene expression genetic alteration result change activity hmts making them oncogenic cancer causing focusing genetic driver cancer epizyme targeted science seek match right medicine with right patient style margin margin bottom font size font family time roman more information visit nbsp epizyme nbsp connect with twitter nbsp epizymerx style margin margin bottom font size font family time roman cautionary note forward looking statement style margin margin bottom font size font family time roman statement this press release about future expectation plan prospect epizyme other statement containing word anticipate believe estimate expect intend plan predict project target potential will would could should continue similar expression constitute forward looking statement within meaning private security litigation reform actual result differ materially from those indicated such forward looking statement result various important factor including uncertainty inherent initiation future clinical study expansion ongoing clinical study availability timing data from ongoing clinical study whether interim result from clinical trial will predictive final result trial result future trial expectation regulatory approval development progress company companion diagnostics availability funding sufficient company foreseeable unforeseeable operating expense capital expenditure requirement other matter that could affect availability commercial potential company therapeutic candidate companion diagnostics other factor discussed risk factor section company annual report form year ended december nbsp that will filed with security exchange commission addition forward looking statement included this press release represent company view date hereof company anticipates that subsequent event development will cause company view change however while company elect update these forward looking statement some point future company specifically disclaims obligation these forward looking statement should relied upon representing company view date subsequent date hereof style margin margin bottom font size font family time roman medium investor style margin margin bottom font size font family time roman manisha style margin margin bottom font size font family time roman epizyme style margin margin bottom font size font family time roman style margin margin bottom font size font family time roman mpai epizyme style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center exhibit style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width style font family time roman font size valign align center valign bottom valign middle rowspan align center eisai press release valign bottom valign align center march style font family time roman font size valign valign bottom valign bottom valign align center eisai table style margin margin bottom font size font family time roman align center statement regarding change strategic partnership with style margin margin bottom font size font family time roman align center epizyme discover develop commercialize style margin margin bottom font size font family time roman align center anticancer therapy targeting epigenetic enzyme style margin margin bottom font size font family time roman eisai headquarters tokyo haruo naito eisai announced today that eisai epizyme headquarters cambridge massachusetts robert gould epizyme have agreed change scope collaboration their worldwide partnership initiated march discover develop commercialize cancer therapeutic targeting epigenetic enzyme style margin margin bottom font size font family time roman march eisai epizyme entered into collaboration agreement concerning discovery development commercialization cancer therapeutic targeting epigenetic enzyme treatment hodgkin cell lymphoma other cancer under this agreement eisai been conducting phase clinical study inhibitor epizyme development code patient with advanced solid tumor hodgkin cell lymphoma style margin margin bottom font size font family time roman eisai epizyme have revised scope their partnership worldwide development commercialization right anticancer therapy targeting including with epizyme assuming responsibility development commercialization region outside japan eisai retaining responsibility development commercialization within japan well having right first negotiation licensing right asia decision change scope partnership agreed upon company consideration priority each company pipeline strategy maximization potential value compound including style margin margin bottom font size font family time roman based this change agreement eisai will receive from epizyme contractual time payment well milestone payment project progress marketing authorization obtained company will royalty another dependent upon sale each company respective sale region after launch style margin margin bottom font size font family time roman eisai considers oncology therapeutic area focus committed development anticancer agent treatment supportive care eisai strives further contribute addressing diverse need increasing benefit provided patient with cancer their family style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman medium inquiry style margin margin bottom font size font family time roman public relation department style margin margin bottom font size font family time roman eisai style margin margin bottom font size font family time roman style margin margin bottom font size font family time roman note editor style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign about epizyme table style margin margin bottom font size font family time roman epizyme clinical stage biopharmaceutical company that discovers develops plan commercialize novel epigenetic therapy cancer patient epizyme built proprietary product platform that company create small molecule inhibitor enzyme known histone methyltransferases hmts hmts part system gene regulation referred epigenetics that control gene expression genetic alteration result change activity hmts making them oncogenic cancer causing focusing genetic driver cancer epizyme targeted science seek match right medicine with right patient personalized approach cancer treatment more information visit epizyme style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign about table style margin margin bottom font size font family time roman protein that make histone methyltransferases hmts that alter gene expression known methylate lysine protein being five major histone group that together help store eukaryotic cell nucleus methylation also known suppress gene transcription believed that regulates cell proliferation have important role carcinogenesis also deletion subunit chromatin remodeling complex occurs nearly malignant rhabdoid tumor rare cancer with particularly poor prognosis antagonistic relationship been demonstrated between biochemical action complex chromatin which relieved deletion potential driving oncogene these cancer therefore important therapeutic target requiring further investigation created through epizyme proprietary product platform first class selective small molecule inhibitor epigenetic enzyme eisai epizyme initiated global strategic partnership march regarding research development marketing targeted therapy lymphoma other cancer influenced these genetic alteration style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman align center asia style margin margin bottom font size font family time roman bahrain bangladesh bhutan burma cambodia china hong kong indonesia south korea phillipines malaysia maldives mongolia nepal singapore lanka taiwan thailand timor leste vietnam body html text document